EA015538B1 - Композиции и способы применения антител к dickkopf-1 и/или -4 - Google Patents

Info

Publication number

EA015538B1

EA015538B1 EA200801679A EA200801679A EA015538B1 EA 015538 B1 EA015538 B1 EA 015538B1 EA 200801679 A EA200801679 A EA 200801679A EA 200801679 A EA200801679 A EA 200801679A EA 015538 B1 EA015538 B1 EA 015538B1

Authority

EA

Eurasian Patent Office

Prior art keywords

antibody

amino acid

antibodies

binding

sequence

Prior art date

2006-01-13

Links

• Espacenet
• Global Dossier
• Discuss

• 238000000034 method Methods 0.000 title abstract description 142
• 239000000203 mixture Substances 0.000 title description 68
• 102100030074 Dickkopf-related protein 1 Human genes 0.000 title 1
• 101710099518 Dickkopf-related protein 1 Proteins 0.000 title 1
• 102100037986 Dickkopf-related protein 4 Human genes 0.000 title 1
• 101710099554 Dickkopf-related protein 4 Proteins 0.000 title 1
• 108090000623 proteins and genes Proteins 0.000 abstract description 179
• 239000012634 fragment Substances 0.000 abstract description 151
• 102000004169 proteins and genes Human genes 0.000 abstract description 125
• 230000000010 osteolytic effect Effects 0.000 abstract description 21
• 230000027455 binding Effects 0.000 description 228
• 241000282414 Homo sapiens Species 0.000 description 213
• 210000004027 cell Anatomy 0.000 description 177
• 125000003275 alpha amino acid group Chemical group 0.000 description 163
• 230000000694 effects Effects 0.000 description 153
• 239000000427 antigen Substances 0.000 description 143
• 108091007433 antigens Proteins 0.000 description 140
• 102000036639 antigens Human genes 0.000 description 140
• 235000018102 proteins Nutrition 0.000 description 113
• 150000001875 compounds Chemical class 0.000 description 105
• 230000014509 gene expression Effects 0.000 description 94
• 239000002773 nucleotide Substances 0.000 description 65
• 125000003729 nucleotide group Chemical group 0.000 description 65
• 241000699670 Mus sp. Species 0.000 description 61
• 206010028980 Neoplasm Diseases 0.000 description 56
• 102000005962 receptors Human genes 0.000 description 56
• 108020003175 receptors Proteins 0.000 description 56
• 239000003814 drug Substances 0.000 description 55
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 52
• 241000699666 Mus <mouse, genus> Species 0.000 description 50
• 229940079593 drug Drugs 0.000 description 49
• 239000008187 granular material Substances 0.000 description 49
• 238000004458 analytical method Methods 0.000 description 47
• 239000013543 active substance Substances 0.000 description 46
• 210000000988 bone and bone Anatomy 0.000 description 45
• 201000010099 disease Diseases 0.000 description 41
• 108091028043 Nucleic acid sequence Proteins 0.000 description 39
• 108060003951 Immunoglobulin Proteins 0.000 description 38
• 102000018358 immunoglobulin Human genes 0.000 description 38
• 230000003472 neutralizing effect Effects 0.000 description 38
• 206010035226 Plasma cell myeloma Diseases 0.000 description 35
• 230000004048 modification Effects 0.000 description 34
• 238000012986 modification Methods 0.000 description 34
• 239000000243 solution Substances 0.000 description 34
• 238000011282 treatment Methods 0.000 description 34
• 235000001014 amino acid Nutrition 0.000 description 32
• 239000003795 chemical substances by application Substances 0.000 description 32
• 210000004602 germ cell Anatomy 0.000 description 32
• 230000006870 function Effects 0.000 description 31
• 230000035772 mutation Effects 0.000 description 31
• 241001465754 Metazoa Species 0.000 description 30
• 208000003076 Osteolysis Diseases 0.000 description 30
• 125000000539 amino acid group Chemical group 0.000 description 30
• 239000003112 inhibitor Substances 0.000 description 30
• 208000029791 lytic metastatic bone lesion Diseases 0.000 description 30
• 208000024891 symptom Diseases 0.000 description 30
• 238000004091 panning Methods 0.000 description 28
• 238000002360 preparation method Methods 0.000 description 28
• 201000011510 cancer Diseases 0.000 description 27
• 210000002966 serum Anatomy 0.000 description 27
• 108020004414 DNA Proteins 0.000 description 26
• 230000008569 process Effects 0.000 description 25
• 101710104662 Enterotoxin type C-3 Proteins 0.000 description 24
• 102100030844 Exocyst complex component 1 Human genes 0.000 description 24
• 108060001084 Luciferase Proteins 0.000 description 24
• 238000006206 glycosylation reaction Methods 0.000 description 23
• 201000000050 myeloid neoplasm Diseases 0.000 description 23
• 239000008194 pharmaceutical composition Substances 0.000 description 23
• 230000001225 therapeutic effect Effects 0.000 description 23
• 230000018109 developmental process Effects 0.000 description 22
• 241000282836 Camelus dromedarius Species 0.000 description 21
• 241000282412 Homo Species 0.000 description 21
• 239000005089 Luciferase Substances 0.000 description 21
• 229940024606 amino acid Drugs 0.000 description 21
• 238000011161 development Methods 0.000 description 21
• 239000013604 expression vector Substances 0.000 description 21
• 230000013595 glycosylation Effects 0.000 description 21
• 230000001965 increasing effect Effects 0.000 description 21
• 108090000765 processed proteins & peptides Proteins 0.000 description 21
• 150000003839 salts Chemical class 0.000 description 21
• 230000008054 signal transmission Effects 0.000 description 21
• 239000013598 vector Substances 0.000 description 21
• 150000001413 amino acids Chemical class 0.000 description 20
• 210000004408 hybridoma Anatomy 0.000 description 20
• 239000002609 medium Substances 0.000 description 20
• 102000004196 processed proteins & peptides Human genes 0.000 description 20
• 101100273247 Arabidopsis thaliana KRP1 gene Proteins 0.000 description 19
• 241000282567 Macaca fascicularis Species 0.000 description 19
• 238000003556 assay Methods 0.000 description 19
• 230000006378 damage Effects 0.000 description 19
• 229920001184 polypeptide Polymers 0.000 description 19
• 102100040837 Galactoside alpha-(1,2)-fucosyltransferase 2 Human genes 0.000 description 18
• 101000893710 Homo sapiens Galactoside alpha-(1,2)-fucosyltransferase 2 Proteins 0.000 description 18
• 101000882403 Staphylococcus aureus Enterotoxin type C-2 Proteins 0.000 description 18
• 238000002474 experimental method Methods 0.000 description 18
• 230000003993 interaction Effects 0.000 description 18
• 230000037361 pathway Effects 0.000 description 17
• 239000000523 sample Substances 0.000 description 17
• 238000007792 addition Methods 0.000 description 16
• 238000005457 optimization Methods 0.000 description 16
• 239000000047 product Substances 0.000 description 16
• 241000894007 species Species 0.000 description 16
• 108020004705 Codon Proteins 0.000 description 15
• 239000002202 Polyethylene glycol Substances 0.000 description 15
• 238000013459 approach Methods 0.000 description 15
• 239000003636 conditioned culture medium Substances 0.000 description 15
• 230000007423 decrease Effects 0.000 description 15
• 230000001419 dependent effect Effects 0.000 description 15
• 238000004519 manufacturing process Methods 0.000 description 15
• 210000000963 osteoblast Anatomy 0.000 description 15
• 229920001223 polyethylene glycol Polymers 0.000 description 15
• 108700005091 Immunoglobulin Genes Proteins 0.000 description 14
• 239000002253 acid Substances 0.000 description 14
• 238000005516 engineering process Methods 0.000 description 14
• 230000002401 inhibitory effect Effects 0.000 description 14
• 230000005764 inhibitory process Effects 0.000 description 14
• 230000005291 magnetic effect Effects 0.000 description 14
• 210000002997 osteoclast Anatomy 0.000 description 14
• 239000002245 particle Substances 0.000 description 14
• 230000035897 transcription Effects 0.000 description 14
• 238000013518 transcription Methods 0.000 description 14
• 108010021625 Immunoglobulin Fragments Proteins 0.000 description 13
• 102000008394 Immunoglobulin Fragments Human genes 0.000 description 13
• 230000001105 regulatory effect Effects 0.000 description 13
• 238000006467 substitution reaction Methods 0.000 description 13
• 210000002303 tibia Anatomy 0.000 description 13
• 210000001519 tissue Anatomy 0.000 description 13
• -1 (diethylamino) ethyl Chemical group 0.000 description 12
• 208000034578 Multiple myelomas Diseases 0.000 description 12
• 239000003937 drug carrier Substances 0.000 description 12
• 238000002649 immunization Methods 0.000 description 12
• 210000004962 mammalian cell Anatomy 0.000 description 12
• 150000007523 nucleic acids Chemical class 0.000 description 12
• 102000039446 nucleic acids Human genes 0.000 description 12
• 108020004707 nucleic acids Proteins 0.000 description 12
• 230000002829 reductive effect Effects 0.000 description 12
• 101710110357 Inhibitor of nuclear factor kappa-B kinase subunit alpha Proteins 0.000 description 11
• 102100021892 Inhibitor of nuclear factor kappa-B kinase subunit alpha Human genes 0.000 description 11
• 241000124008 Mammalia Species 0.000 description 11
• 241000700159 Rattus Species 0.000 description 11
• 101000882406 Staphylococcus aureus Enterotoxin type C-1 Proteins 0.000 description 11
• 108700019146 Transgenes Proteins 0.000 description 11
• 230000009471 action Effects 0.000 description 11
• 239000002246 antineoplastic agent Substances 0.000 description 11
• 230000015572 biosynthetic process Effects 0.000 description 11
• 238000010790 dilution Methods 0.000 description 11
• 239000012895 dilution Substances 0.000 description 11
• 208000035475 disorder Diseases 0.000 description 11
• 239000012636 effector Substances 0.000 description 11
• 230000004927 fusion Effects 0.000 description 11
• 229910052739 hydrogen Inorganic materials 0.000 description 11
• 230000003053 immunization Effects 0.000 description 11
• 229940127121 immunoconjugate Drugs 0.000 description 11
• 239000007943 implant Substances 0.000 description 11
• 238000011534 incubation Methods 0.000 description 11
• 238000001802 infusion Methods 0.000 description 11
• 230000035800 maturation Effects 0.000 description 11
• 206010060862 Prostate cancer Diseases 0.000 description 10
• 239000004480 active ingredient Substances 0.000 description 10
• 239000002671 adjuvant Substances 0.000 description 10
• 230000008859 change Effects 0.000 description 10
• 230000004069 differentiation Effects 0.000 description 10
• 238000002347 injection Methods 0.000 description 10
• 239000007924 injection Substances 0.000 description 10
• 210000004881 tumor cell Anatomy 0.000 description 10
• 238000005406 washing Methods 0.000 description 10
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 9
• 108091000080 Phosphotransferase Proteins 0.000 description 9
• 208000000236 Prostatic Neoplasms Diseases 0.000 description 9
• 230000009824 affinity maturation Effects 0.000 description 9
• 239000005557 antagonist Substances 0.000 description 9
• 230000004071 biological effect Effects 0.000 description 9
• 230000037182 bone density Effects 0.000 description 9
• 238000001514 detection method Methods 0.000 description 9
• 150000002632 lipids Chemical class 0.000 description 9
• 239000000825 pharmaceutical preparation Substances 0.000 description 9
• 102000020233 phosphotransferase Human genes 0.000 description 9
• 230000035755 proliferation Effects 0.000 description 9
• 229940124597 therapeutic agent Drugs 0.000 description 9
• 230000009261 transgenic effect Effects 0.000 description 9
• 102000015735 Beta-catenin Human genes 0.000 description 8
• 108060000903 Beta-catenin Proteins 0.000 description 8
• 206010065687 Bone loss Diseases 0.000 description 8
• 241000283707 Capra Species 0.000 description 8
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 8
• 206010027476 Metastases Diseases 0.000 description 8
• 241001529936 Murinae Species 0.000 description 8
• 108010003723 Single-Domain Antibodies Proteins 0.000 description 8
• 230000000890 antigenic effect Effects 0.000 description 8
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 8
• 230000000903 blocking effect Effects 0.000 description 8
• 238000006243 chemical reaction Methods 0.000 description 8
• 239000003153 chemical reaction reagent Substances 0.000 description 8
• 229960005091 chloramphenicol Drugs 0.000 description 8
• WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 8
• 238000012217 deletion Methods 0.000 description 8
• 230000037430 deletion Effects 0.000 description 8
• 230000012010 growth Effects 0.000 description 8
• 210000003494 hepatocyte Anatomy 0.000 description 8
• 230000001976 improved effect Effects 0.000 description 8
• 230000001582 osteoblastic effect Effects 0.000 description 8
• 238000012216 screening Methods 0.000 description 8
• 239000006228 supernatant Substances 0.000 description 8
• 239000000725 suspension Substances 0.000 description 8
• 238000004448 titration Methods 0.000 description 8
• 102000002260 Alkaline Phosphatase Human genes 0.000 description 7
• 108020004774 Alkaline Phosphatase Proteins 0.000 description 7
• 102000016359 Fibronectins Human genes 0.000 description 7
• 108010067306 Fibronectins Proteins 0.000 description 7
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 7
• 102000004067 Osteocalcin Human genes 0.000 description 7
• 108090000573 Osteocalcin Proteins 0.000 description 7
• 229930012538 Paclitaxel Natural products 0.000 description 7
• 108010076504 Protein Sorting Signals Proteins 0.000 description 7
• 229910052770 Uranium Inorganic materials 0.000 description 7
• 230000003321 amplification Effects 0.000 description 7
• 230000003042 antagnostic effect Effects 0.000 description 7
• 230000001580 bacterial effect Effects 0.000 description 7
• 239000000090 biomarker Substances 0.000 description 7
• 210000001072 colon Anatomy 0.000 description 7
• 230000009260 cross reactivity Effects 0.000 description 7
• 239000000284 extract Substances 0.000 description 7
• 239000008103 glucose Substances 0.000 description 7
• 229940072221 immunoglobulins Drugs 0.000 description 7
• BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 7
• 239000000463 material Substances 0.000 description 7
• 230000007246 mechanism Effects 0.000 description 7
• 230000001404 mediated effect Effects 0.000 description 7
• 238000002703 mutagenesis Methods 0.000 description 7
• 231100000350 mutagenesis Toxicity 0.000 description 7
• 238000003199 nucleic acid amplification method Methods 0.000 description 7
• 229960001592 paclitaxel Drugs 0.000 description 7
• 238000000746 purification Methods 0.000 description 7
• 239000000126 substance Substances 0.000 description 7
• 239000003826 tablet Substances 0.000 description 7
• RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 7
• 238000002560 therapeutic procedure Methods 0.000 description 7
• 208000006386 Bone Resorption Diseases 0.000 description 6
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
• 208000001132 Osteoporosis Diseases 0.000 description 6
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
• 108010090804 Streptavidin Proteins 0.000 description 6
• 239000002585 base Substances 0.000 description 6
• 210000004369 blood Anatomy 0.000 description 6
• 239000008280 blood Substances 0.000 description 6
• 230000037396 body weight Effects 0.000 description 6
• 230000024279 bone resorption Effects 0.000 description 6
• 210000000481 breast Anatomy 0.000 description 6
• 239000000872 buffer Substances 0.000 description 6
• 238000002512 chemotherapy Methods 0.000 description 6
• 238000010367 cloning Methods 0.000 description 6
• 238000010494 dissociation reaction Methods 0.000 description 6
• 230000005593 dissociations Effects 0.000 description 6
• 239000003534 dna topoisomerase inhibitor Substances 0.000 description 6
• 231100000673 dose–response relationship Toxicity 0.000 description 6
• 210000003414 extremity Anatomy 0.000 description 6
• 238000002523 gelfiltration Methods 0.000 description 6
• 239000001963 growth medium Substances 0.000 description 6
• 238000002513 implantation Methods 0.000 description 6
• 238000001990 intravenous administration Methods 0.000 description 6
• 239000003446 ligand Substances 0.000 description 6
• 239000002502 liposome Substances 0.000 description 6
• 210000004072 lung Anatomy 0.000 description 6
• 239000003550 marker Substances 0.000 description 6
• 239000000178 monomer Substances 0.000 description 6
• 230000005298 paramagnetic effect Effects 0.000 description 6
• 238000007911 parenteral administration Methods 0.000 description 6
• 230000002062 proliferating effect Effects 0.000 description 6
• 238000000159 protein binding assay Methods 0.000 description 6
• 108091008598 receptor tyrosine kinases Proteins 0.000 description 6
• 102000027426 receptor tyrosine kinases Human genes 0.000 description 6
• 230000004044 response Effects 0.000 description 6
• 238000002741 site-directed mutagenesis Methods 0.000 description 6
• 239000002904 solvent Substances 0.000 description 6
• 238000010561 standard procedure Methods 0.000 description 6
• 238000007920 subcutaneous administration Methods 0.000 description 6
• 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 6
• 229940044693 topoisomerase inhibitor Drugs 0.000 description 6
• 238000011830 transgenic mouse model Methods 0.000 description 6
• 238000002054 transplantation Methods 0.000 description 6
• 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 6
• 101100288232 Arabidopsis thaliana KRP2 gene Proteins 0.000 description 5
• 101100288240 Arabidopsis thaliana KRP6 gene Proteins 0.000 description 5
• 241000894006 Bacteria Species 0.000 description 5
• 229940122361 Bisphosphonate Drugs 0.000 description 5
• 201000009030 Carcinoma Diseases 0.000 description 5
• 235000010469 Glycine max Nutrition 0.000 description 5
• 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 5
• 108091006905 Human Serum Albumin Proteins 0.000 description 5
• 102000008100 Human Serum Albumin Human genes 0.000 description 5
• 108050006654 Lipocalin Proteins 0.000 description 5
• 102000019298 Lipocalin Human genes 0.000 description 5
• 101710181812 Methionine aminopeptidase Proteins 0.000 description 5
• 101100345589 Mus musculus Mical1 gene Proteins 0.000 description 5
• 102000003982 Parathyroid hormone Human genes 0.000 description 5
• 108090000445 Parathyroid hormone Proteins 0.000 description 5
• 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 5
• 230000002159 abnormal effect Effects 0.000 description 5
• 230000004913 activation Effects 0.000 description 5
• 229940046836 anti-estrogen Drugs 0.000 description 5
• 230000001833 anti-estrogenic effect Effects 0.000 description 5
• 239000002256 antimetabolite Substances 0.000 description 5
• 239000003963 antioxidant agent Substances 0.000 description 5
• 235000006708 antioxidants Nutrition 0.000 description 5
• 239000003886 aromatase inhibitor Substances 0.000 description 5
• 150000004663 bisphosphonates Chemical class 0.000 description 5
• 230000008499 blood brain barrier function Effects 0.000 description 5
• 210000001218 blood-brain barrier Anatomy 0.000 description 5
• 230000004097 bone metabolism Effects 0.000 description 5
• 210000004556 brain Anatomy 0.000 description 5
• 230000001413 cellular effect Effects 0.000 description 5
• 230000000295 complement effect Effects 0.000 description 5
• 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 5
• 229940127089 cytotoxic agent Drugs 0.000 description 5
• 231100000135 cytotoxicity Toxicity 0.000 description 5
• 230000003013 cytotoxicity Effects 0.000 description 5
• 230000003247 decreasing effect Effects 0.000 description 5
• 239000006185 dispersion Substances 0.000 description 5
• 239000002552 dosage form Substances 0.000 description 5
• 210000000981 epithelium Anatomy 0.000 description 5
• 239000000328 estrogen antagonist Substances 0.000 description 5
• 238000009472 formulation Methods 0.000 description 5
• 238000005259 measurement Methods 0.000 description 5
• 230000010534 mechanism of action Effects 0.000 description 5
• GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 5
• 201000008968 osteosarcoma Diseases 0.000 description 5
• 230000002018 overexpression Effects 0.000 description 5
• 210000000496 pancreas Anatomy 0.000 description 5
• 239000000199 parathyroid hormone Substances 0.000 description 5
• 229960001319 parathyroid hormone Drugs 0.000 description 5
• 229920000136 polysorbate Polymers 0.000 description 5
• 210000002307 prostate Anatomy 0.000 description 5
• 150000003230 pyrimidines Chemical class 0.000 description 5
• 230000007420 reactivation Effects 0.000 description 5
• 230000028327 secretion Effects 0.000 description 5
• 230000035945 sensitivity Effects 0.000 description 5
• 230000004083 survival effect Effects 0.000 description 5
• 238000001890 transfection Methods 0.000 description 5
• PZIRTMUUDNWDHP-BGPOSVGRSA-N (e)-2-cyano-n-[2-[[(e)-2-cyano-3-(3,4-dihydroxyphenyl)prop-2-enoyl]amino]ethyl]-3-(3,4-dihydroxyphenyl)prop-2-enamide Chemical compound C1=C(O)C(O)=CC=C1\C=C(/C#N)C(=O)NCCNC(=O)C(\C#N)=C\C1=CC=C(O)C(O)=C1 PZIRTMUUDNWDHP-BGPOSVGRSA-N 0.000 description 4
• 206010069754 Acquired gene mutation Diseases 0.000 description 4
• 208000024827 Alzheimer disease Diseases 0.000 description 4
• 102000008102 Ankyrins Human genes 0.000 description 4
• 108010049777 Ankyrins Proteins 0.000 description 4
• 229940122815 Aromatase inhibitor Drugs 0.000 description 4
• 206010005949 Bone cancer Diseases 0.000 description 4
• 208000018084 Bone neoplasm Diseases 0.000 description 4
• 208000026310 Breast neoplasm Diseases 0.000 description 4
• 102000000844 Cell Surface Receptors Human genes 0.000 description 4
• 108010001857 Cell Surface Receptors Proteins 0.000 description 4
• 241000282693 Cercopithecidae Species 0.000 description 4
• 241000251730 Chondrichthyes Species 0.000 description 4
• 108091035707 Consensus sequence Proteins 0.000 description 4
• 241000701022 Cytomegalovirus Species 0.000 description 4
• 102000053602 DNA Human genes 0.000 description 4
• AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
• 238000002965 ELISA Methods 0.000 description 4
• 102100029112 Endothelin-converting enzyme 1 Human genes 0.000 description 4
• HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 4
• 241000287828 Gallus gallus Species 0.000 description 4
• 244000068988 Glycine max Species 0.000 description 4
• 101000914051 Homo sapiens Probable cytosolic iron-sulfur protein assembly protein CIAO1 Proteins 0.000 description 4
• 208000029725 Metabolic bone disease Diseases 0.000 description 4
• 102000016943 Muramidase Human genes 0.000 description 4
• 108010014251 Muramidase Proteins 0.000 description 4
• 241000699660 Mus musculus Species 0.000 description 4
• 206010028289 Muscle atrophy Diseases 0.000 description 4
• 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 4
• 206010049088 Osteopenia Diseases 0.000 description 4
• 102100026405 Probable cytosolic iron-sulfur protein assembly protein CIAO1 Human genes 0.000 description 4
• 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 4
• 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 4
• NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 4
• MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 4
• 108090000848 Ubiquitin Proteins 0.000 description 4
• 102000044159 Ubiquitin Human genes 0.000 description 4
• 238000010521 absorption reaction Methods 0.000 description 4
• 230000003213 activating effect Effects 0.000 description 4
• 230000001772 anti-angiogenic effect Effects 0.000 description 4
• 230000000340 anti-metabolite Effects 0.000 description 4
• 230000001028 anti-proliverative effect Effects 0.000 description 4
• 230000000692 anti-sense effect Effects 0.000 description 4
• 230000000259 anti-tumor effect Effects 0.000 description 4
• 229940100197 antimetabolite Drugs 0.000 description 4
• 229960000397 bevacizumab Drugs 0.000 description 4
• 239000011230 binding agent Substances 0.000 description 4
• 238000004422 calculation algorithm Methods 0.000 description 4
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
• 235000013330 chicken meat Nutrition 0.000 description 4
• 239000011248 coating agent Substances 0.000 description 4
• 238000000576 coating method Methods 0.000 description 4
• 230000002860 competitive effect Effects 0.000 description 4
• 230000004540 complement-dependent cytotoxicity Effects 0.000 description 4
• 230000037029 cross reaction Effects 0.000 description 4
• 206010012601 diabetes mellitus Diseases 0.000 description 4
• 238000005401 electroluminescence Methods 0.000 description 4
• 230000002708 enhancing effect Effects 0.000 description 4
• 210000003238 esophagus Anatomy 0.000 description 4
• 229960005167 everolimus Drugs 0.000 description 4
• 239000000945 filler Substances 0.000 description 4
• 238000004108 freeze drying Methods 0.000 description 4
• 230000028993 immune response Effects 0.000 description 4
• 208000015181 infectious disease Diseases 0.000 description 4
• 230000005865 ionizing radiation Effects 0.000 description 4
• 210000004698 lymphocyte Anatomy 0.000 description 4
• 239000006166 lysate Substances 0.000 description 4
• 235000010335 lysozyme Nutrition 0.000 description 4
• 239000004325 lysozyme Substances 0.000 description 4
• 229960000274 lysozyme Drugs 0.000 description 4
• 238000013507 mapping Methods 0.000 description 4
• 210000002752 melanocyte Anatomy 0.000 description 4
• 230000020763 muscle atrophy Effects 0.000 description 4
• 201000000585 muscular atrophy Diseases 0.000 description 4
• 239000003921 oil Substances 0.000 description 4
• 235000019198 oils Nutrition 0.000 description 4
• 230000002246 oncogenic effect Effects 0.000 description 4
• 230000006320 pegylation Effects 0.000 description 4
• 239000000546 pharmaceutical excipient Substances 0.000 description 4
• 238000002428 photodynamic therapy Methods 0.000 description 4
• 210000001236 prokaryotic cell Anatomy 0.000 description 4
• 230000002035 prolonged effect Effects 0.000 description 4
• RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 4
• ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 4
• 238000003259 recombinant expression Methods 0.000 description 4
• 238000007634 remodeling Methods 0.000 description 4
• 108091008146 restriction endonucleases Proteins 0.000 description 4
• 230000003248 secreting effect Effects 0.000 description 4
• 230000019491 signal transduction Effects 0.000 description 4
• 229960002930 sirolimus Drugs 0.000 description 4
• QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 4
• DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 4
• 230000037439 somatic mutation Effects 0.000 description 4
• 230000009870 specific binding Effects 0.000 description 4
• 239000007858 starting material Substances 0.000 description 4
• 150000003431 steroids Chemical class 0.000 description 4
• 239000000758 substrate Substances 0.000 description 4
• 230000001629 suppression Effects 0.000 description 4
• 238000012360 testing method Methods 0.000 description 4
• 230000009466 transformation Effects 0.000 description 4
• 238000013519 translation Methods 0.000 description 4
• 229960000575 trastuzumab Drugs 0.000 description 4
• 230000004614 tumor growth Effects 0.000 description 4
• 241000701447 unidentified baculovirus Species 0.000 description 4
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
• 229910052727 yttrium Inorganic materials 0.000 description 4
• DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 4
• GVJHHUAWPYXKBD-IEOSBIPESA-N (R)-alpha-Tocopherol Natural products OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 3
• IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 3
• 239000005541 ACE inhibitor Substances 0.000 description 3
• 108091006112 ATPases Proteins 0.000 description 3
• 102000057290 Adenosine Triphosphatases Human genes 0.000 description 3
• 229920001817 Agar Polymers 0.000 description 3
• 201000004384 Alopecia Diseases 0.000 description 3
• 229940097396 Aminopeptidase inhibitor Drugs 0.000 description 3
• 241000283690 Bos taurus Species 0.000 description 3
• 102000055006 Calcitonin Human genes 0.000 description 3
• 108060001064 Calcitonin Proteins 0.000 description 3
• 241000699802 Cricetulus griseus Species 0.000 description 3
• 229940122204 Cyclooxygenase inhibitor Drugs 0.000 description 3
• 108090000695 Cytokines Proteins 0.000 description 3
• 102000004127 Cytokines Human genes 0.000 description 3
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
• 102000004190 Enzymes Human genes 0.000 description 3
• 108090000790 Enzymes Proteins 0.000 description 3
• GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 3
• 108010010803 Gelatin Proteins 0.000 description 3
• 108090000288 Glycoproteins Proteins 0.000 description 3
• 102000003886 Glycoproteins Human genes 0.000 description 3
• 102400000932 Gonadoliberin-1 Human genes 0.000 description 3
• 229940122588 Heparanase inhibitor Drugs 0.000 description 3
• 101500026183 Homo sapiens Gonadoliberin-1 Proteins 0.000 description 3
• 101000609219 Homo sapiens Polyadenylate-binding protein 4 Proteins 0.000 description 3
• 102000003839 Human Proteins Human genes 0.000 description 3
• 108090000144 Human Proteins Proteins 0.000 description 3
• 102000014150 Interferons Human genes 0.000 description 3
• 108010050904 Interferons Proteins 0.000 description 3
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 3
• 239000005517 L01XE01 - Imatinib Substances 0.000 description 3
• 239000005411 L01XE02 - Gefitinib Substances 0.000 description 3
• 239000005551 L01XE03 - Erlotinib Substances 0.000 description 3
• 241001175904 Labeo bata Species 0.000 description 3
• 241000282553 Macaca Species 0.000 description 3
• 229930195725 Mannitol Natural products 0.000 description 3
• 102000029749 Microtubule Human genes 0.000 description 3
• 108091022875 Microtubule Proteins 0.000 description 3
• 208000008589 Obesity Diseases 0.000 description 3
• 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 3
• 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 3
• 102100039424 Polyadenylate-binding protein 4 Human genes 0.000 description 3
• 229920001213 Polysorbate 20 Polymers 0.000 description 3
• 108010029485 Protein Isoforms Proteins 0.000 description 3
• 102000001708 Protein Isoforms Human genes 0.000 description 3
• 108020004511 Recombinant DNA Proteins 0.000 description 3
• 229940123934 Reductase inhibitor Drugs 0.000 description 3
• 108700008625 Reporter Genes Proteins 0.000 description 3
• 108010041388 Ribonucleotide Reductases Proteins 0.000 description 3
• 102000000505 Ribonucleotide Reductases Human genes 0.000 description 3
• 101150007309 SOK3 gene Proteins 0.000 description 3
• 229940121856 Somatostatin receptor antagonist Drugs 0.000 description 3
• 108010017842 Telomerase Proteins 0.000 description 3
• 229940123582 Telomerase inhibitor Drugs 0.000 description 3
• JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 3
• 241000700605 Viruses Species 0.000 description 3
• 108010046377 Whey Proteins Proteins 0.000 description 3
• 230000002378 acidificating effect Effects 0.000 description 3
• 150000007513 acids Chemical class 0.000 description 3
• 239000008272 agar Substances 0.000 description 3
• 239000000556 agonist Substances 0.000 description 3
• 239000002168 alkylating agent Substances 0.000 description 3
• 229940100198 alkylating agent Drugs 0.000 description 3
• 239000003098 androgen Substances 0.000 description 3
• 230000000964 angiostatic effect Effects 0.000 description 3
• 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 3
• 230000002280 anti-androgenic effect Effects 0.000 description 3
• 230000000719 anti-leukaemic effect Effects 0.000 description 3
• 230000003262 anti-osteoporosis Effects 0.000 description 3
• 239000000051 antiandrogen Substances 0.000 description 3
• 239000011324 bead Substances 0.000 description 3
• 230000008512 biological response Effects 0.000 description 3
• 230000005540 biological transmission Effects 0.000 description 3
• 210000001185 bone marrow Anatomy 0.000 description 3
• BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 3
• 229960004015 calcitonin Drugs 0.000 description 3
• 239000002775 capsule Substances 0.000 description 3
• 150000001720 carbohydrates Chemical class 0.000 description 3
• 235000014633 carbohydrates Nutrition 0.000 description 3
• 238000004113 cell culture Methods 0.000 description 3
• 230000024245 cell differentiation Effects 0.000 description 3
• 210000000170 cell membrane Anatomy 0.000 description 3
• 238000005119 centrifugation Methods 0.000 description 3
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
• 239000002299 complementary DNA Substances 0.000 description 3
• 238000010276 construction Methods 0.000 description 3
• 238000007796 conventional method Methods 0.000 description 3
• 230000009509 cortical damage Effects 0.000 description 3
• 239000003246 corticosteroid Substances 0.000 description 3
• 229960001334 corticosteroids Drugs 0.000 description 3
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
• 229960002433 cysteine Drugs 0.000 description 3
• 235000018417 cysteine Nutrition 0.000 description 3
• 229960003957 dexamethasone Drugs 0.000 description 3
• UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 3
• 239000002612 dispersion medium Substances 0.000 description 3
• 229940088598 enzyme Drugs 0.000 description 3
• HESCAJZNRMSMJG-HGYUPSKWSA-N epothilone A Natural products O=C1[C@H](C)[C@H](O)[C@H](C)CCC[C@H]2O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C HESCAJZNRMSMJG-HGYUPSKWSA-N 0.000 description 3
• AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 3
• 229960001433 erlotinib Drugs 0.000 description 3
• 210000003527 eukaryotic cell Anatomy 0.000 description 3
• 238000011156 evaluation Methods 0.000 description 3
• 229960002949 fluorouracil Drugs 0.000 description 3
• 230000005714 functional activity Effects 0.000 description 3
• XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 3
• 229920000159 gelatin Polymers 0.000 description 3
• 239000008273 gelatin Substances 0.000 description 3
• 235000019322 gelatine Nutrition 0.000 description 3
• 235000011852 gelatine desserts Nutrition 0.000 description 3
• 235000011187 glycerol Nutrition 0.000 description 3
• XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 3
• 229960001442 gonadorelin Drugs 0.000 description 3
• 208000024963 hair loss Diseases 0.000 description 3
• 230000003676 hair loss Effects 0.000 description 3
• 229960002411 imatinib Drugs 0.000 description 3
• KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 3
• 230000005847 immunogenicity Effects 0.000 description 3
• 238000001727 in vivo Methods 0.000 description 3
• 239000003978 infusion fluid Substances 0.000 description 3
• 239000004615 ingredient Substances 0.000 description 3
• 230000000977 initiatory effect Effects 0.000 description 3
• 238000007918 intramuscular administration Methods 0.000 description 3
• 238000007912 intraperitoneal administration Methods 0.000 description 3
• 210000003734 kidney Anatomy 0.000 description 3
• 239000000787 lecithin Substances 0.000 description 3
• 235000010445 lecithin Nutrition 0.000 description 3
• 229940067606 lecithin Drugs 0.000 description 3
• 210000002414 leg Anatomy 0.000 description 3
• 210000004185 liver Anatomy 0.000 description 3
• 238000003670 luciferase enzyme activity assay Methods 0.000 description 3
• 210000001161 mammalian embryo Anatomy 0.000 description 3
• 239000000594 mannitol Substances 0.000 description 3
• 235000010355 mannitol Nutrition 0.000 description 3
• 239000011159 matrix material Substances 0.000 description 3
• 239000003771 matrix metalloproteinase inhibitor Substances 0.000 description 3
• 229940121386 matrix metalloproteinase inhibitor Drugs 0.000 description 3
• 229960001428 mercaptopurine Drugs 0.000 description 3
• 229960000485 methotrexate Drugs 0.000 description 3
• 210000004688 microtubule Anatomy 0.000 description 3
• 239000003607 modifier Substances 0.000 description 3
• 210000003205 muscle Anatomy 0.000 description 3
• 108010087904 neutravidin Proteins 0.000 description 3
• 231100000252 nontoxic Toxicity 0.000 description 3
• 230000003000 nontoxic effect Effects 0.000 description 3
• 235000020824 obesity Nutrition 0.000 description 3
• 231100000590 oncogenic Toxicity 0.000 description 3
• 230000003204 osmotic effect Effects 0.000 description 3
• 230000011164 ossification Effects 0.000 description 3
• 230000036961 partial effect Effects 0.000 description 3
• 230000007170 pathology Effects 0.000 description 3
• 239000000816 peptidomimetic Substances 0.000 description 3
• 238000002823 phage display Methods 0.000 description 3
• 239000008177 pharmaceutical agent Substances 0.000 description 3
• 230000003285 pharmacodynamic effect Effects 0.000 description 3
• 239000013612 plasmid Substances 0.000 description 3
• 229920005862 polyol Polymers 0.000 description 3
• 150000003077 polyols Chemical class 0.000 description 3
• 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
• 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
• 239000013641 positive control Substances 0.000 description 3
• 239000000843 powder Substances 0.000 description 3
• 239000003755 preservative agent Substances 0.000 description 3
• 230000003449 preventive effect Effects 0.000 description 3
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
• 230000000069 prophylactic effect Effects 0.000 description 3
• 239000002599 prostaglandin synthase inhibitor Substances 0.000 description 3
• 208000023958 prostate neoplasm Diseases 0.000 description 3
• 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 description 3
• 238000001959 radiotherapy Methods 0.000 description 3
• 230000002441 reversible effect Effects 0.000 description 3
• 239000012679 serum free medium Substances 0.000 description 3
• 238000001542 size-exclusion chromatography Methods 0.000 description 3
• 210000003491 skin Anatomy 0.000 description 3
• 239000011780 sodium chloride Substances 0.000 description 3
• 238000001179 sorption measurement Methods 0.000 description 3
• 238000001228 spectrum Methods 0.000 description 3
• 210000004988 splenocyte Anatomy 0.000 description 3
• 238000012289 standard assay Methods 0.000 description 3
• 230000001954 sterilising effect Effects 0.000 description 3
• 235000000346 sugar Nutrition 0.000 description 3
• 150000008163 sugars Chemical class 0.000 description 3
• 230000002195 synergetic effect Effects 0.000 description 3
• 239000003277 telomerase inhibitor Substances 0.000 description 3
• 230000032258 transport Effects 0.000 description 3
• 235000021119 whey protein Nutrition 0.000 description 3
• 210000005253 yeast cell Anatomy 0.000 description 3
• YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
• DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 2
• MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
• OTXNTMVVOOBZCV-UHFFFAOYSA-N 2R-gamma-tocotrienol Natural products OC1=C(C)C(C)=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1 OTXNTMVVOOBZCV-UHFFFAOYSA-N 0.000 description 2
• AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 2
• ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
• BUROJSBIWGDYCN-GAUTUEMISA-N AP 23573 Chemical compound C1C[C@@H](OP(C)(C)=O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 BUROJSBIWGDYCN-GAUTUEMISA-N 0.000 description 2
• 229940122076 Adenosylmethionine decarboxylase inhibitor Drugs 0.000 description 2
• 229920000936 Agarose Polymers 0.000 description 2
• 101100167260 Arabidopsis thaliana CIA2 gene Proteins 0.000 description 2
• 101100043388 Arabidopsis thaliana SRK2D gene Proteins 0.000 description 2
• BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 2
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
• DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
• 101710189812 Bilin-binding protein Proteins 0.000 description 2
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
• 239000004322 Butylated hydroxytoluene Substances 0.000 description 2
• NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
• FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
• 101100446042 Caenorhabditis elegans lbp-6 gene Proteins 0.000 description 2
• KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 2
• 241000282472 Canis lupus familiaris Species 0.000 description 2
• GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 2
• GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 2
• 208000005623 Carcinogenesis Diseases 0.000 description 2
• 102000014914 Carrier Proteins Human genes 0.000 description 2
• 102000008186 Collagen Human genes 0.000 description 2
• 108010035532 Collagen Proteins 0.000 description 2
• 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
• 108020004635 Complementary DNA Proteins 0.000 description 2
• MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 2
• 241000938605 Crocodylia Species 0.000 description 2
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
• 229920002307 Dextran Polymers 0.000 description 2
• HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 2
• QXRSDHAAWVKZLJ-OXZHEXMSSA-N Epothilone B Natural products O=C1[C@H](C)[C@H](O)[C@@H](C)CCC[C@@]2(C)O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C QXRSDHAAWVKZLJ-OXZHEXMSSA-N 0.000 description 2
• 241000283086 Equidae Species 0.000 description 2
• 102100036908 Equilibrative nucleoside transporter 4 Human genes 0.000 description 2
• DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 2
• 241000282326 Felis catus Species 0.000 description 2
• VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 description 2
• 229930182566 Gentamicin Natural products 0.000 description 2
• CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
• BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 2
• 108010069236 Goserelin Proteins 0.000 description 2
• 101100094863 Homo sapiens SLC29A4 gene Proteins 0.000 description 2
• 101000628693 Homo sapiens Serine/threonine-protein kinase 25 Proteins 0.000 description 2
• XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 2
• XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 2
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
• XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
• DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
• HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
• AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
• COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
• AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
• QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
• KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
• 241000282838 Lama Species 0.000 description 2
• 206010027452 Metastases to bone Diseases 0.000 description 2
• 101100172512 Mus musculus Epha2 gene Proteins 0.000 description 2
• ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 2
• 241000737052 Naso hexacanthus Species 0.000 description 2
• 208000008636 Neoplastic Processes Diseases 0.000 description 2
• 102000008108 Osteoprotegerin Human genes 0.000 description 2
• 108010035042 Osteoprotegerin Proteins 0.000 description 2
• 241001494479 Pecora Species 0.000 description 2
• ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
• 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 2
• 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 2
• NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
• 239000004698 Polyethylene Substances 0.000 description 2
• 241000288906 Primates Species 0.000 description 2
• ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
• 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 2
• 102000001253 Protein Kinase Human genes 0.000 description 2
• 108090000315 Protein Kinase C Proteins 0.000 description 2
• 102000003923 Protein Kinase C Human genes 0.000 description 2
• 102000009516 Protein Serine-Threonine Kinases Human genes 0.000 description 2
• 108010009341 Protein Serine-Threonine Kinases Proteins 0.000 description 2
• 108091005682 Receptor kinases Proteins 0.000 description 2
• 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
• 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
• 101100355601 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) RAD53 gene Proteins 0.000 description 2
• 238000012300 Sequence Analysis Methods 0.000 description 2
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
• 102100026737 Serine/threonine-protein kinase 25 Human genes 0.000 description 2
• 102100029437 Serine/threonine-protein kinase A-Raf Human genes 0.000 description 2
• 210000001744 T-lymphocyte Anatomy 0.000 description 2
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
• 239000004473 Threonine Substances 0.000 description 2
• 101710183280 Topoisomerase Proteins 0.000 description 2
• QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
• KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
• 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
• 102000007544 Whey Proteins Human genes 0.000 description 2
• AIWRTTMUVOZGPW-HSPKUQOVSA-N abarelix Chemical compound C([C@@H](C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)N(C)C(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 AIWRTTMUVOZGPW-HSPKUQOVSA-N 0.000 description 2
• 229960002184 abarelix Drugs 0.000 description 2
• 108010023617 abarelix Proteins 0.000 description 2
• 230000006978 adaptation Effects 0.000 description 2
• 230000002776 aggregation Effects 0.000 description 2
• 238000004220 aggregation Methods 0.000 description 2
• RZFHLOLGZPDCHJ-DLQZEEBKSA-N alpha-Tocotrienol Natural products Oc1c(C)c(C)c2O[C@@](CC/C=C(/CC/C=C(\CC/C=C(\C)/C)/C)\C)(C)CCc2c1C RZFHLOLGZPDCHJ-DLQZEEBKSA-N 0.000 description 2
• 150000001412 amines Chemical class 0.000 description 2
• 229960003437 aminoglutethimide Drugs 0.000 description 2
• ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 2
• 239000003263 anabolic agent Substances 0.000 description 2
• 229940124325 anabolic agent Drugs 0.000 description 2
• 230000001195 anabolic effect Effects 0.000 description 2
• 239000012491 analyte Substances 0.000 description 2
• 230000033115 angiogenesis Effects 0.000 description 2
• 239000002333 angiotensin II receptor antagonist Substances 0.000 description 2
• 239000000400 angiotensin II type 1 receptor blocker Substances 0.000 description 2
• 239000003242 anti bacterial agent Substances 0.000 description 2
• 230000000844 anti-bacterial effect Effects 0.000 description 2
• 230000000733 anti-osteolytic effect Effects 0.000 description 2
• 239000003429 antifungal agent Substances 0.000 description 2
• 229940121375 antifungal agent Drugs 0.000 description 2
• 239000012736 aqueous medium Substances 0.000 description 2
• 239000007864 aqueous solution Substances 0.000 description 2
• 235000009582 asparagine Nutrition 0.000 description 2
• 229960001230 asparagine Drugs 0.000 description 2
• VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 2
• 230000009286 beneficial effect Effects 0.000 description 2
• 108091008324 binding proteins Proteins 0.000 description 2
• 230000033228 biological regulation Effects 0.000 description 2
• 239000002981 blocking agent Substances 0.000 description 2
• 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
• 229940095259 butylated hydroxytoluene Drugs 0.000 description 2
• 210000004899 c-terminal region Anatomy 0.000 description 2
• VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 2
• 229940127093 camptothecin Drugs 0.000 description 2
• 230000036952 cancer formation Effects 0.000 description 2
• 229960004117 capecitabine Drugs 0.000 description 2
• 229910002091 carbon monoxide Inorganic materials 0.000 description 2
• 229960004562 carboplatin Drugs 0.000 description 2
• 239000001768 carboxy methyl cellulose Substances 0.000 description 2
• 231100000504 carcinogenesis Toxicity 0.000 description 2
• 239000013592 cell lysate Substances 0.000 description 2
• 229960005395 cetuximab Drugs 0.000 description 2
• 238000012512 characterization method Methods 0.000 description 2
• 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
• OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
• 238000004587 chromatography analysis Methods 0.000 description 2
• DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
• 229960004316 cisplatin Drugs 0.000 description 2
• 230000004186 co-expression Effects 0.000 description 2
• 206010009887 colitis Diseases 0.000 description 2
• 229920001436 collagen Polymers 0.000 description 2
• 238000010835 comparative analysis Methods 0.000 description 2
• 239000000470 constituent Substances 0.000 description 2
• 239000013068 control sample Substances 0.000 description 2
• 230000001054 cortical effect Effects 0.000 description 2
• 238000005520 cutting process Methods 0.000 description 2
• 229960004397 cyclophosphamide Drugs 0.000 description 2
• 229960001251 denosumab Drugs 0.000 description 2
• 238000013461 design Methods 0.000 description 2
• 239000003085 diluting agent Substances 0.000 description 2
• 239000000539 dimer Substances 0.000 description 2
• 238000004090 dissolution Methods 0.000 description 2
• 238000009826 distribution Methods 0.000 description 2
• VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 2
• 229960003668 docetaxel Drugs 0.000 description 2
• 230000003828 downregulation Effects 0.000 description 2
• 229960004679 doxorubicin Drugs 0.000 description 2
• 239000008298 dragée Substances 0.000 description 2
• 239000012893 effector ligand Substances 0.000 description 2
• 238000004520 electroporation Methods 0.000 description 2
• 230000008030 elimination Effects 0.000 description 2
• 238000003379 elimination reaction Methods 0.000 description 2
• 238000010828 elution Methods 0.000 description 2
• 210000002257 embryonic structure Anatomy 0.000 description 2
• 239000003995 emulsifying agent Substances 0.000 description 2
• 239000003623 enhancer Substances 0.000 description 2
• 229960001904 epirubicin Drugs 0.000 description 2
• QXRSDHAAWVKZLJ-PVYNADRNSA-N epothilone B Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 QXRSDHAAWVKZLJ-PVYNADRNSA-N 0.000 description 2
• 150000002148 esters Chemical class 0.000 description 2
• 229940011871 estrogen Drugs 0.000 description 2
• 239000000262 estrogen Substances 0.000 description 2
• 229960003399 estrone Drugs 0.000 description 2
• VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 2
• 229960005420 etoposide Drugs 0.000 description 2
• 229960000255 exemestane Drugs 0.000 description 2
• 239000012091 fetal bovine serum Substances 0.000 description 2
• 238000001914 filtration Methods 0.000 description 2
• GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 2
• MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
• 229960002258 fulvestrant Drugs 0.000 description 2
• 108020001507 fusion proteins Proteins 0.000 description 2
• 102000037865 fusion proteins Human genes 0.000 description 2
• 229960002584 gefitinib Drugs 0.000 description 2
• QTQAWLPCGQOSGP-GBTDJJJQSA-N geldanamycin Chemical class N1C(=O)\C(C)=C/C=C\[C@@H](OC)[C@H](OC(N)=O)\C(C)=C/[C@@H](C)[C@@H](O)[C@H](OC)C[C@@H](C)CC2=C(OC)C(=O)C=C1C2=O QTQAWLPCGQOSGP-GBTDJJJQSA-N 0.000 description 2
• 229960005277 gemcitabine Drugs 0.000 description 2
• SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 2
• 238000010353 genetic engineering Methods 0.000 description 2
• 229960002518 gentamicin Drugs 0.000 description 2
• 229960002913 goserelin Drugs 0.000 description 2
• 239000003102 growth factor Substances 0.000 description 2
• 230000036541 health Effects 0.000 description 2
• 230000002489 hematologic effect Effects 0.000 description 2
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
• 210000005260 human cell Anatomy 0.000 description 2
• 230000028996 humoral immune response Effects 0.000 description 2
• 238000009396 hybridization Methods 0.000 description 2
• JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
• 229960000908 idarubicin Drugs 0.000 description 2
• HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 2
• 229960001101 ifosfamide Drugs 0.000 description 2
• 230000001900 immune effect Effects 0.000 description 2
• 210000000987 immune system Anatomy 0.000 description 2
• 238000001114 immunoprecipitation Methods 0.000 description 2
• 229910052500 inorganic mineral Inorganic materials 0.000 description 2
• 229940047124 interferons Drugs 0.000 description 2
• 238000011835 investigation Methods 0.000 description 2
• 239000011630 iodine Substances 0.000 description 2
• 229910052740 iodine Inorganic materials 0.000 description 2
• UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 2
• 229960004768 irinotecan Drugs 0.000 description 2
• 229960000310 isoleucine Drugs 0.000 description 2
• AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
• 229940043355 kinase inhibitor Drugs 0.000 description 2
• 229960003881 letrozole Drugs 0.000 description 2
• HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 2
• 238000004020 luminiscence type Methods 0.000 description 2
• KHPKQFYUPIUARC-UHFFFAOYSA-N lumiracoxib Chemical compound OC(=O)CC1=CC(C)=CC=C1NC1=C(F)C=CC=C1Cl KHPKQFYUPIUARC-UHFFFAOYSA-N 0.000 description 2
• 239000011777 magnesium Substances 0.000 description 2
• 239000006249 magnetic particle Substances 0.000 description 2
• 230000003211 malignant effect Effects 0.000 description 2
• 201000001441 melanoma Diseases 0.000 description 2
• 210000002901 mesenchymal stem cell Anatomy 0.000 description 2
• 230000001394 metastastic effect Effects 0.000 description 2
• 206010061289 metastatic neoplasm Diseases 0.000 description 2
• BMGQWWVMWDBQGC-IIFHNQTCSA-N midostaurin Chemical compound CN([C@H]1[C@H]([C@]2(C)O[C@@H](N3C4=CC=CC=C4C4=C5C(=O)NCC5=C5C6=CC=CC=C6N2C5=C43)C1)OC)C(=O)C1=CC=CC=C1 BMGQWWVMWDBQGC-IIFHNQTCSA-N 0.000 description 2
• 229950010895 midostaurin Drugs 0.000 description 2
• 239000011707 mineral Substances 0.000 description 2
• 229960001156 mitoxantrone Drugs 0.000 description 2
• KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 2
• 238000002156 mixing Methods 0.000 description 2
• 238000001823 molecular biology technique Methods 0.000 description 2
• 238000006386 neutralization reaction Methods 0.000 description 2
• 229910052757 nitrogen Inorganic materials 0.000 description 2
• XXUPLYBCNPLTIW-UHFFFAOYSA-N octadec-7-ynoic acid Chemical compound CCCCCCCCCCC#CCCCCCC(O)=O XXUPLYBCNPLTIW-UHFFFAOYSA-N 0.000 description 2
• 230000008520 organization Effects 0.000 description 2
• 230000001599 osteoclastic effect Effects 0.000 description 2
• 230000001009 osteoporotic effect Effects 0.000 description 2
• DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 2
• 229960001756 oxaliplatin Drugs 0.000 description 2
• 239000005022 packaging material Substances 0.000 description 2
• 244000052769 pathogen Species 0.000 description 2
• 239000008188 pellet Substances 0.000 description 2
• 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
• COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
• 239000003757 phosphotransferase inhibitor Substances 0.000 description 2
• 210000002826 placenta Anatomy 0.000 description 2
• 210000004180 plasmocyte Anatomy 0.000 description 2
• BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
• 150000003058 platinum compounds Chemical class 0.000 description 2
• 230000002265 prevention Effects 0.000 description 2
• 238000012545 processing Methods 0.000 description 2
• 108060006633 protein kinase Proteins 0.000 description 2
• 229950010131 puromycin Drugs 0.000 description 2
• 230000005855 radiation Effects 0.000 description 2
• 230000002285 radioactive effect Effects 0.000 description 2
• BKXVVCILCIUCLG-UHFFFAOYSA-N raloxifene hydrochloride Chemical compound [H+].[Cl-].C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 BKXVVCILCIUCLG-UHFFFAOYSA-N 0.000 description 2
• 229960002119 raloxifene hydrochloride Drugs 0.000 description 2
• 108091006084 receptor activators Proteins 0.000 description 2
• 230000001603 reducing effect Effects 0.000 description 2
• 230000010076 replication Effects 0.000 description 2
• 238000012552 review Methods 0.000 description 2
• 229960004641 rituximab Drugs 0.000 description 2
• 150000003384 small molecules Chemical class 0.000 description 2
• 239000011734 sodium Substances 0.000 description 2
• 229910052708 sodium Inorganic materials 0.000 description 2
• 239000012064 sodium phosphate buffer Substances 0.000 description 2
• 229940054269 sodium pyruvate Drugs 0.000 description 2
• 239000000600 sorbitol Substances 0.000 description 2
• 101150087667 spk1 gene Proteins 0.000 description 2
• 210000000952 spleen Anatomy 0.000 description 2
• 230000003393 splenic effect Effects 0.000 description 2
• 230000006641 stabilisation Effects 0.000 description 2
• 238000011105 stabilization Methods 0.000 description 2
• 238000012409 standard PCR amplification Methods 0.000 description 2
• HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical class C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 description 2
• 238000004659 sterilization and disinfection Methods 0.000 description 2
• 238000003860 storage Methods 0.000 description 2
• UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
• 239000004094 surface-active agent Substances 0.000 description 2
• 229960001603 tamoxifen Drugs 0.000 description 2
• NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 2
• 229960001278 teniposide Drugs 0.000 description 2
• 229960003604 testosterone Drugs 0.000 description 2
• 230000004797 therapeutic response Effects 0.000 description 2
• WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 2
• 239000003104 tissue culture media Substances 0.000 description 2
• UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 2
• 229960000303 topotecan Drugs 0.000 description 2
• 229960005267 tositumomab Drugs 0.000 description 2
• 230000005748 tumor development Effects 0.000 description 2
• 241000701161 unidentified adenovirus Species 0.000 description 2
• 230000003827 upregulation Effects 0.000 description 2
• 239000004474 valine Substances 0.000 description 2
• 210000004509 vascular smooth muscle cell Anatomy 0.000 description 2
• KDQAABAKXDWYSZ-PNYVAJAMSA-N vinblastine sulfate Chemical compound OS(O)(=O)=O.C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 KDQAABAKXDWYSZ-PNYVAJAMSA-N 0.000 description 2
• 229960004982 vinblastine sulfate Drugs 0.000 description 2
• AQTQHPDCURKLKT-JKDPCDLQSA-N vincristine sulfate Chemical compound OS(O)(=O)=O.C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 AQTQHPDCURKLKT-JKDPCDLQSA-N 0.000 description 2
• 229960002110 vincristine sulfate Drugs 0.000 description 2
• 230000003612 virological effect Effects 0.000 description 2
• 229930003231 vitamin Natural products 0.000 description 2
• 235000013343 vitamin Nutrition 0.000 description 2
• 239000011782 vitamin Substances 0.000 description 2
• 229940088594 vitamin Drugs 0.000 description 2
• 150000003722 vitamin derivatives Chemical class 0.000 description 2
• 238000001262 western blot Methods 0.000 description 2
• 239000000080 wetting agent Substances 0.000 description 2
• 229960004276 zoledronic acid Drugs 0.000 description 2
• XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 description 2
• 239000002076 α-tocopherol Substances 0.000 description 2
• 235000004835 α-tocopherol Nutrition 0.000 description 2
• GZIFEOYASATJEH-VHFRWLAGSA-N δ-tocopherol Chemical compound OC1=CC(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 GZIFEOYASATJEH-VHFRWLAGSA-N 0.000 description 2
• QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
• XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
• BIDNLKIUORFRQP-XYGFDPSESA-N (2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 description 1
• JWOGUUIOCYMBPV-GMFLJSBRSA-N (3S,6S,9S,12R)-3-[(2S)-Butan-2-yl]-6-[(1-methoxyindol-3-yl)methyl]-9-(6-oxooctyl)-1,4,7,10-tetrazabicyclo[10.4.0]hexadecane-2,5,8,11-tetrone Chemical compound N1C(=O)[C@H](CCCCCC(=O)CC)NC(=O)[C@H]2CCCCN2C(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]1CC1=CN(OC)C2=CC=CC=C12 JWOGUUIOCYMBPV-GMFLJSBRSA-N 0.000 description 1
• FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 1
• 125000000027 (C1-C10) alkoxy group Chemical group 0.000 description 1
• LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 1
• RMBWOGPXEHGMSQ-UDWIEESQSA-N (e)-2-hydroxy-3-[4-[[2-(2-methyl-1h-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide Chemical compound CC=1NC2=CC=CC=C2C=1CCNCC1=CC=C(\C=C(\O)C(N)=O)C=C1 RMBWOGPXEHGMSQ-UDWIEESQSA-N 0.000 description 1
• FDCWAWBPIGTNBN-FYJGNVAPSA-N (e)-2-hydroxy-3-[4-[[2-hydroxyethyl-[2-(1h-indol-3-yl)ethyl]amino]methyl]phenyl]prop-2-enamide Chemical compound C1=CC(\C=C(\O)C(=O)N)=CC=C1CN(CCO)CCC1=CNC2=CC=CC=C12 FDCWAWBPIGTNBN-FYJGNVAPSA-N 0.000 description 1
• QRPSQQUYPMFERG-LFYBBSHMSA-N (e)-5-[3-(benzenesulfonamido)phenyl]-n-hydroxypent-2-en-4-ynamide Chemical compound ONC(=O)\C=C\C#CC1=CC=CC(NS(=O)(=O)C=2C=CC=CC=2)=C1 QRPSQQUYPMFERG-LFYBBSHMSA-N 0.000 description 1
• BLRBOMBBUUGKFU-SREVYHEPSA-N (z)-4-[[4-(4-chlorophenyl)-5-(2-methoxy-2-oxoethyl)-1,3-thiazol-2-yl]amino]-4-oxobut-2-enoic acid Chemical compound S1C(NC(=O)\C=C/C(O)=O)=NC(C=2C=CC(Cl)=CC=2)=C1CC(=O)OC BLRBOMBBUUGKFU-SREVYHEPSA-N 0.000 description 1
• QVVJLUAZVYFOOV-UHFFFAOYSA-N 1-(1-adamantyloxy)adamantane Chemical compound C1C(C2)CC(C3)CC2CC13OC(C1)(C2)CC3CC2CC1C3 QVVJLUAZVYFOOV-UHFFFAOYSA-N 0.000 description 1
• ZESRJSPZRDMNHY-YFWFAHHUSA-N 11-deoxycorticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 ZESRJSPZRDMNHY-YFWFAHHUSA-N 0.000 description 1
• WHBHBVVOGNECLV-OBQKJFGGSA-N 11-deoxycortisol Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 WHBHBVVOGNECLV-OBQKJFGGSA-N 0.000 description 1
• DBPWSSGDRRHUNT-CEGNMAFCSA-N 17α-hydroxyprogesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 DBPWSSGDRRHUNT-CEGNMAFCSA-N 0.000 description 1
• VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
• CKTSBUTUHBMZGZ-SHYZEUOFSA-N 2'‐deoxycytidine Chemical class O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 CKTSBUTUHBMZGZ-SHYZEUOFSA-N 0.000 description 1
• UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 1
• PXBFMLJZNCDSMP-UHFFFAOYSA-N 2-Aminobenzamide Chemical class NC(=O)C1=CC=CC=C1N PXBFMLJZNCDSMP-UHFFFAOYSA-N 0.000 description 1
• QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
• BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
• JXPDNDHCMMOJPC-UHFFFAOYSA-N 2-hydroxybutanedinitrile Chemical compound N#CC(O)CC#N JXPDNDHCMMOJPC-UHFFFAOYSA-N 0.000 description 1
• ODADKLYLWWCHNB-UHFFFAOYSA-N 2R-delta-tocotrienol Natural products OC1=CC(C)=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1 ODADKLYLWWCHNB-UHFFFAOYSA-N 0.000 description 1
• KYHPMCZXXRPOKS-ZJWYQBPBSA-N 3,7-dihydropurin-6-one;2-hydrazinyl-1h-pteridin-4-one;1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC=NC2=C1NC=N2.C1=CN=C2C(=O)NC(NN)=NC2=N1.O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 KYHPMCZXXRPOKS-ZJWYQBPBSA-N 0.000 description 1
• CLPFFLWZZBQMAO-UHFFFAOYSA-N 4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)benzonitrile Chemical compound C1=CC(C#N)=CC=C1C1N2C=NC=C2CCC1 CLPFFLWZZBQMAO-UHFFFAOYSA-N 0.000 description 1
• SQSOZLKKUXKFJQ-UHFFFAOYSA-N 4-[(2,5-dihydroxyphenyl)methylamino]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1NCC1=CC(O)=CC=C1O SQSOZLKKUXKFJQ-UHFFFAOYSA-N 0.000 description 1
• FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
• DMEGQEWPMXDRMO-UHFFFAOYSA-N 4-phenylpyrimidin-2-amine Chemical class NC1=NC=CC(C=2C=CC=CC=2)=N1 DMEGQEWPMXDRMO-UHFFFAOYSA-N 0.000 description 1
• NMUSYJAQQFHJEW-UHFFFAOYSA-N 5-Azacytidine Natural products O=C1N=C(N)N=CN1C1C(O)C(O)C(CO)O1 NMUSYJAQQFHJEW-UHFFFAOYSA-N 0.000 description 1
• XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 description 1
• NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
• STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
• 101150059573 AGTR1 gene Proteins 0.000 description 1
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
• 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
• 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
• 102000009027 Albumins Human genes 0.000 description 1
• 108010088751 Albumins Proteins 0.000 description 1
• OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 description 1
• 108700028369 Alleles Proteins 0.000 description 1
• 102100039160 Amiloride-sensitive amine oxidase [copper-containing] Human genes 0.000 description 1
• 235000002198 Annona diversifolia Nutrition 0.000 description 1
• 101100273858 Anopheles gambiae CecB gene Proteins 0.000 description 1
• 101100273868 Anopheles gambiae CecC gene Proteins 0.000 description 1
• 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
• 108091023037 Aptamer Proteins 0.000 description 1
• 101100274255 Arabidopsis thaliana CHER1 gene Proteins 0.000 description 1
• 101100069028 Arabidopsis thaliana GK3 gene Proteins 0.000 description 1
• 101100288238 Arabidopsis thaliana KRP5 gene Proteins 0.000 description 1
• 101100203025 Arabidopsis thaliana SERK4 gene Proteins 0.000 description 1
• 101100533498 Arabidopsis thaliana SIA2 gene Proteins 0.000 description 1
• 239000004475 Arginine Substances 0.000 description 1
• XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 description 1
• 208000010392 Bone Fractures Diseases 0.000 description 1
• 208000020084 Bone disease Diseases 0.000 description 1
• 206010006002 Bone pain Diseases 0.000 description 1
• 206010006187 Breast cancer Diseases 0.000 description 1
• 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
• 108091007914 CDKs Proteins 0.000 description 1
• 101100324465 Caenorhabditis elegans arr-1 gene Proteins 0.000 description 1
• 101100328518 Caenorhabditis elegans cnt-1 gene Proteins 0.000 description 1
• 101100173447 Caenorhabditis elegans ger-1 gene Proteins 0.000 description 1
• 101100446036 Caenorhabditis elegans lbp-5 gene Proteins 0.000 description 1
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
• 241000282828 Camelus bactrianus Species 0.000 description 1
• 101710167800 Capsid assembly scaffolding protein Proteins 0.000 description 1
• 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
• 102000005600 Cathepsins Human genes 0.000 description 1
• 108010084457 Cathepsins Proteins 0.000 description 1
• 101100059604 Ceratitis capitata CEC2 gene Proteins 0.000 description 1
• PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 1
• 101150010736 Clrn1 gene Proteins 0.000 description 1
• 108091026890 Coding region Proteins 0.000 description 1
• 206010009944 Colon cancer Diseases 0.000 description 1
• OMFXVFTZEKFJBZ-UHFFFAOYSA-N Corticosterone Natural products O=C1CCC2(C)C3C(O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 OMFXVFTZEKFJBZ-UHFFFAOYSA-N 0.000 description 1
• 102000003903 Cyclin-dependent kinases Human genes 0.000 description 1
• 108090000266 Cyclin-dependent kinases Proteins 0.000 description 1
• 101710112752 Cytotoxin Proteins 0.000 description 1
• IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
• GZIFEOYASATJEH-UHFFFAOYSA-N D-delta tocopherol Natural products OC1=CC(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 GZIFEOYASATJEH-UHFFFAOYSA-N 0.000 description 1
• SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
• 239000012650 DNA demethylating agent Substances 0.000 description 1
• 229940045805 DNA demethylating agent Drugs 0.000 description 1
• CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
• 108010002156 Depsipeptides Proteins 0.000 description 1
• DLVJMFOLJOOWFS-UHFFFAOYSA-N Depudecin Natural products CC(O)C1OC1C=CC1C(C(O)C=C)O1 DLVJMFOLJOOWFS-UHFFFAOYSA-N 0.000 description 1
• FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
• 238000009007 Diagnostic Kit Methods 0.000 description 1
• 235000017274 Diospyros sandwicensis Nutrition 0.000 description 1
• 101100510329 Drosophila melanogaster Pkc53E gene Proteins 0.000 description 1
• 101100059603 Drosophila virilis Cec3 gene Proteins 0.000 description 1
• 102000001301 EGF receptor Human genes 0.000 description 1
• 108060006698 EGF receptor Proteins 0.000 description 1
• 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
• LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
• 241000196324 Embryophyta Species 0.000 description 1
• 108010061435 Enalapril Proteins 0.000 description 1
• 102100021616 Ephrin type-A receptor 4 Human genes 0.000 description 1
• 102400001368 Epidermal growth factor Human genes 0.000 description 1
• 101800003838 Epidermal growth factor Proteins 0.000 description 1
• YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
• 241000588724 Escherichia coli Species 0.000 description 1
• 101001039942 Escherichia coli (strain K12) Glycerate 2-kinase Proteins 0.000 description 1
• 101001039941 Escherichia coli (strain K12) Glycerate 3-kinase Proteins 0.000 description 1
• 239000001856 Ethyl cellulose Substances 0.000 description 1
• PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
• 108091029865 Exogenous DNA Proteins 0.000 description 1
• 108050001049 Extracellular proteins Proteins 0.000 description 1
• 108091008794 FGF receptors Proteins 0.000 description 1
• 102000007317 Farnesyltranstransferase Human genes 0.000 description 1
• 108010007508 Farnesyltranstransferase Proteins 0.000 description 1
• 102000008946 Fibrinogen Human genes 0.000 description 1
• 108010049003 Fibrinogen Proteins 0.000 description 1
• 102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 description 1
• 108090000331 Firefly luciferases Proteins 0.000 description 1
• BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
• PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
• 102000006471 Fucosyltransferases Human genes 0.000 description 1
• 108010019236 Fucosyltransferases Proteins 0.000 description 1
• JRZJKWGQFNTSRN-UHFFFAOYSA-N Geldanamycin Natural products C1C(C)CC(OC)C(O)C(C)C=C(C)C(OC(N)=O)C(OC)CCC=C(C)C(=O)NC2=CC(=O)C(OC)=C1C2=O JRZJKWGQFNTSRN-UHFFFAOYSA-N 0.000 description 1
• 208000032612 Glial tumor Diseases 0.000 description 1
• 206010018338 Glioma Diseases 0.000 description 1
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
• 239000004471 Glycine Substances 0.000 description 1
• 108700023372 Glycosyltransferases Proteins 0.000 description 1
• 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
• 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
• 108010009202 Growth Factor Receptors Proteins 0.000 description 1
• 102000009465 Growth Factor Receptors Human genes 0.000 description 1
• HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 description 1
• 229920002971 Heparan sulfate Polymers 0.000 description 1
• 102100024025 Heparanase Human genes 0.000 description 1
• HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
• 108090000353 Histone deacetylase Proteins 0.000 description 1
• 102000003964 Histone deacetylase Human genes 0.000 description 1
• 101000905392 Homo sapiens Glycerol kinase Proteins 0.000 description 1
• 101000888011 Homo sapiens Glycerol kinase 2 Proteins 0.000 description 1
• 101001047819 Homo sapiens Heparanase Proteins 0.000 description 1
• 101001043764 Homo sapiens Inhibitor of nuclear factor kappa-B kinase subunit alpha Proteins 0.000 description 1
• 101001043594 Homo sapiens Low-density lipoprotein receptor-related protein 5 Proteins 0.000 description 1
• 101001024872 Homo sapiens N-acetylgalactosamine kinase Proteins 0.000 description 1
• 101000602930 Homo sapiens Nuclear receptor coactivator 2 Proteins 0.000 description 1
• 101001131829 Homo sapiens P protein Proteins 0.000 description 1
• 101001090813 Homo sapiens Proteasome subunit alpha type-6 Proteins 0.000 description 1
• 101000801195 Homo sapiens TLE family member 5 Proteins 0.000 description 1
• 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
• 101150090950 Hsc70-1 gene Proteins 0.000 description 1
• VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
• 206010020843 Hyperthermia Diseases 0.000 description 1
• FDGQSTZJBFJUBT-UHFFFAOYSA-N Hypoxanthine Natural products O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 1
• UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
• MPBVHIBUJCELCL-UHFFFAOYSA-N Ibandronate Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 description 1
• 206010061218 Inflammation Diseases 0.000 description 1
• 102000008070 Interferon-gamma Human genes 0.000 description 1
• 108010074328 Interferon-gamma Proteins 0.000 description 1
• ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
• ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
• 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
• QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
• SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
• 229930182816 L-glutamine Natural products 0.000 description 1
• ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
• KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
• 241000408529 Libra Species 0.000 description 1
• 108010007859 Lisinopril Proteins 0.000 description 1
• 102100021926 Low-density lipoprotein receptor-related protein 5 Human genes 0.000 description 1
• DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
• 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
• 239000006142 Luria-Bertani Agar Substances 0.000 description 1
• 102000008072 Lymphokines Human genes 0.000 description 1
• 108010074338 Lymphokines Proteins 0.000 description 1
• 206010025323 Lymphomas Diseases 0.000 description 1
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
• 239000004472 Lysine Substances 0.000 description 1
• 229940124761 MMP inhibitor Drugs 0.000 description 1
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
• PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 1
• 102000018697 Membrane Proteins Human genes 0.000 description 1
• 108010052285 Membrane Proteins Proteins 0.000 description 1
• 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
• UWWDHYUMIORJTA-HSQYWUDLSA-N Moexipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC(OC)=C(OC)C=C2C1)C(O)=O)CC1=CC=CC=C1 UWWDHYUMIORJTA-HSQYWUDLSA-N 0.000 description 1
• 101100396982 Mus musculus Inmt gene Proteins 0.000 description 1
• 102100035044 Myosin light chain kinase, smooth muscle Human genes 0.000 description 1
• 101710198035 Myosin light chain kinase, smooth muscle Proteins 0.000 description 1
• PTJGLFIIZFVFJV-UHFFFAOYSA-N N'-hydroxy-N-(3-pyridinyl)octanediamide Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CN=C1 PTJGLFIIZFVFJV-UHFFFAOYSA-N 0.000 description 1
• 230000004988 N-glycosylation Effects 0.000 description 1
• GPVKLYONJSSZFL-UHFFFAOYSA-N NSC 750259 Natural products CCC(C)C=CC(O)C(O)C(O)C(OC)C(=O)NC1CCCCNC1=O GPVKLYONJSSZFL-UHFFFAOYSA-N 0.000 description 1
• 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 1
• 102100037226 Nuclear receptor coactivator 2 Human genes 0.000 description 1
• 108091005461 Nucleic proteins Proteins 0.000 description 1
• JWOGUUIOCYMBPV-UHFFFAOYSA-N OT-Key 11219 Natural products N1C(=O)C(CCCCCC(=O)CC)NC(=O)C2CCCCN2C(=O)C(C(C)CC)NC(=O)C1CC1=CN(OC)C2=CC=CC=C12 JWOGUUIOCYMBPV-UHFFFAOYSA-N 0.000 description 1
• 108091034117 Oligonucleotide Proteins 0.000 description 1
• 108700020796 Oncogene Proteins 0.000 description 1
• 102000043276 Oncogene Human genes 0.000 description 1
• 206010031264 Osteonecrosis Diseases 0.000 description 1
• 208000012868 Overgrowth Diseases 0.000 description 1
• 238000012408 PCR amplification Methods 0.000 description 1
• 229930182555 Penicillin Natural products 0.000 description 1
• JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
• 102000007079 Peptide Fragments Human genes 0.000 description 1
• 108010033276 Peptide Fragments Proteins 0.000 description 1
• 241000577979 Peromyscus spicilegus Species 0.000 description 1
• 241000907661 Pieris rapae Species 0.000 description 1
• 229920002732 Polyanhydride Polymers 0.000 description 1
• 229920000954 Polyglycolide Polymers 0.000 description 1
• 241001505332 Polyomavirus sp. Species 0.000 description 1
• 239000004743 Polypropylene Substances 0.000 description 1
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
• 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
• 229910052774 Proactinium Inorganic materials 0.000 description 1
• 101710130420 Probable capsid assembly scaffolding protein Proteins 0.000 description 1
• ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
• 101800004937 Protein C Proteins 0.000 description 1
• 108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
• 229940127395 Ribonucleotide Reductase Inhibitors Drugs 0.000 description 1
• 102220469221 S-adenosyl-L-methionine-dependent tRNA 4-demethylwyosine synthase TYW1B_E18A_mutation Human genes 0.000 description 1
• 101150048104 SEY1 gene Proteins 0.000 description 1
• 229910004438 SUB2 Inorganic materials 0.000 description 1
• 101100256906 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) SIC1 gene Proteins 0.000 description 1
• 102400000827 Saposin-D Human genes 0.000 description 1
• 101800001700 Saposin-D Proteins 0.000 description 1
• 240000005499 Sasa Species 0.000 description 1
• 101150081327 Sb gene Proteins 0.000 description 1
• 101710204410 Scaffold protein Proteins 0.000 description 1
• 101100296591 Schizosaccharomyces pombe (strain 972 / ATCC 24843) pck2 gene Proteins 0.000 description 1
• 101100150366 Schizosaccharomyces pombe (strain 972 / ATCC 24843) sks2 gene Proteins 0.000 description 1
• 101100311330 Schizosaccharomyces pombe (strain 972 / ATCC 24843) uap56 gene Proteins 0.000 description 1
• 206010070834 Sensitisation Diseases 0.000 description 1
• 229920002684 Sepharose Polymers 0.000 description 1
• 201000004283 Shwachman-Diamond syndrome Diseases 0.000 description 1
• 102000004584 Somatomedin Receptors Human genes 0.000 description 1
• 108010017622 Somatomedin Receptors Proteins 0.000 description 1
• 108050001286 Somatostatin Receptor Proteins 0.000 description 1
• 102000011096 Somatostatin receptor Human genes 0.000 description 1
• 241000251778 Squalus acanthias Species 0.000 description 1
• 241000191967 Staphylococcus aureus Species 0.000 description 1
• 229920002472 Starch Polymers 0.000 description 1
• 101710172711 Structural protein Proteins 0.000 description 1
• 208000000389 T-cell leukemia Diseases 0.000 description 1
• 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 1
• FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
• 241000961863 Tasata Species 0.000 description 1
• 229940123237 Taxane Drugs 0.000 description 1
• BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
• 239000004098 Tetracycline Substances 0.000 description 1
• 241000718541 Tetragastris balsamifera Species 0.000 description 1
• 108010022394 Threonine synthase Proteins 0.000 description 1
• DKJJVAGXPKPDRL-UHFFFAOYSA-N Tiludronic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)SC1=CC=C(Cl)C=C1 DKJJVAGXPKPDRL-UHFFFAOYSA-N 0.000 description 1
• VXFJYXUZANRPDJ-WTNASJBWSA-N Trandopril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@H]2CCCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 VXFJYXUZANRPDJ-WTNASJBWSA-N 0.000 description 1
• 102000040945 Transcription factor Human genes 0.000 description 1
• 108091023040 Transcription factor Proteins 0.000 description 1
• 102000004357 Transferases Human genes 0.000 description 1
• 108090000992 Transferases Proteins 0.000 description 1
• 229930189037 Trapoxin Natural products 0.000 description 1
• RTKIYFITIVXBLE-UHFFFAOYSA-N Trichostatin A Natural products ONC(=O)C=CC(C)=CC(C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-UHFFFAOYSA-N 0.000 description 1
• 239000007983 Tris buffer Substances 0.000 description 1
• 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
• 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
• 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
• 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
• 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
• 229940122803 Vinca alkaloid Drugs 0.000 description 1
• 208000008383 Wilms tumor Diseases 0.000 description 1
• 229910052769 Ytterbium Inorganic materials 0.000 description 1
• 230000005856 abnormality Effects 0.000 description 1
• 239000003070 absorption delaying agent Substances 0.000 description 1
• 239000008351 acetate buffer Substances 0.000 description 1
• DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
• 239000008186 active pharmaceutical agent Substances 0.000 description 1
• 238000005917 acylation reaction Methods 0.000 description 1
• 239000000654 additive Substances 0.000 description 1
• 230000000996 additive effect Effects 0.000 description 1
• 230000001464 adherent effect Effects 0.000 description 1
• 210000001789 adipocyte Anatomy 0.000 description 1
• 210000003486 adipose tissue brown Anatomy 0.000 description 1
• 230000011759 adipose tissue development Effects 0.000 description 1
• 238000001042 affinity chromatography Methods 0.000 description 1
• 238000000246 agarose gel electrophoresis Methods 0.000 description 1
• 230000001270 agonistic effect Effects 0.000 description 1
• 235000004279 alanine Nutrition 0.000 description 1
• 150000001298 alcohols Chemical class 0.000 description 1
• 150000001299 aldehydes Chemical class 0.000 description 1
• 229960004343 alendronic acid Drugs 0.000 description 1
• 125000001931 aliphatic group Chemical group 0.000 description 1
• 239000003513 alkali Substances 0.000 description 1
• 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
• 150000001342 alkaline earth metals Chemical class 0.000 description 1
• 229930013930 alkaloid Natural products 0.000 description 1
• 238000005804 alkylation reaction Methods 0.000 description 1
• SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
• 229940087168 alpha tocopherol Drugs 0.000 description 1
• 230000004075 alteration Effects 0.000 description 1
• HESIBZMZTMHXQS-UHFFFAOYSA-M alumanyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[AlH2] HESIBZMZTMHXQS-UHFFFAOYSA-M 0.000 description 1
• 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
• 150000001408 amides Chemical class 0.000 description 1
• 229960002932 anastrozole Drugs 0.000 description 1
• YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 1
• 229960005471 androstenedione Drugs 0.000 description 1
• AEMFNILZOJDQLW-UHFFFAOYSA-N androstenedione Natural products O=C1CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 AEMFNILZOJDQLW-UHFFFAOYSA-N 0.000 description 1
• 239000004037 angiogenesis inhibitor Substances 0.000 description 1
• 229940045799 anthracyclines and related substance Drugs 0.000 description 1
• 150000004056 anthraquinones Chemical class 0.000 description 1
• 230000001093 anti-cancer Effects 0.000 description 1
• 230000003388 anti-hormonal effect Effects 0.000 description 1
• 229940121363 anti-inflammatory agent Drugs 0.000 description 1
• 239000002260 anti-inflammatory agent Substances 0.000 description 1
• 230000003110 anti-inflammatory effect Effects 0.000 description 1
• 230000001130 anti-lysozyme effect Effects 0.000 description 1
• 230000009830 antibody antigen interaction Effects 0.000 description 1
• 238000011319 anticancer therapy Methods 0.000 description 1
• 239000003472 antidiabetic agent Substances 0.000 description 1
• 229940125708 antidiabetic agent Drugs 0.000 description 1
• 210000000612 antigen-presenting cell Anatomy 0.000 description 1
• 239000003080 antimitotic agent Substances 0.000 description 1
• 230000003078 antioxidant effect Effects 0.000 description 1
• 239000000074 antisense oligonucleotide Substances 0.000 description 1
• 238000012230 antisense oligonucleotides Methods 0.000 description 1
• 229940027991 antiseptic and disinfectant quinoline derivative Drugs 0.000 description 1
• 108010082820 apicidin Proteins 0.000 description 1
• 229930186608 apicidin Natural products 0.000 description 1
• 230000006907 apoptotic process Effects 0.000 description 1
• 239000007900 aqueous suspension Substances 0.000 description 1
• 239000008135 aqueous vehicle Substances 0.000 description 1
• 150000008209 arabinosides Chemical class 0.000 description 1
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
• 229940046844 aromatase inhibitors Drugs 0.000 description 1
• 159000000032 aromatic acids Chemical class 0.000 description 1
• 125000003118 aryl group Chemical group 0.000 description 1
• 125000004104 aryloxy group Chemical group 0.000 description 1
• 235000010323 ascorbic acid Nutrition 0.000 description 1
• 229960005070 ascorbic acid Drugs 0.000 description 1
• 239000011668 ascorbic acid Substances 0.000 description 1
• 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
• 235000003704 aspartic acid Nutrition 0.000 description 1
• 230000005784 autoimmunity Effects 0.000 description 1
• 229960002756 azacitidine Drugs 0.000 description 1
• 210000003719 b-lymphocyte Anatomy 0.000 description 1
• 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
• 229960004530 benazepril Drugs 0.000 description 1
• 229930195545 bengamide Natural products 0.000 description 1
• 125000000649 benzylidene group Chemical group [H]C(=[*])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
• OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
• CHDPSNLJFOQTRK-UHFFFAOYSA-N betaxolol hydrochloride Chemical compound [Cl-].C1=CC(OCC(O)C[NH2+]C(C)C)=CC=C1CCOCC1CC1 CHDPSNLJFOQTRK-UHFFFAOYSA-N 0.000 description 1
• 229960004347 betaxolol hydrochloride Drugs 0.000 description 1
• 229960000997 bicalutamide Drugs 0.000 description 1
• 230000003115 biocidal effect Effects 0.000 description 1
• 229920000249 biocompatible polymer Polymers 0.000 description 1
• 230000008033 biological extinction Effects 0.000 description 1
• 238000001574 biopsy Methods 0.000 description 1
• 235000020958 biotin Nutrition 0.000 description 1
• 239000011616 biotin Substances 0.000 description 1
• 229960002685 biotin Drugs 0.000 description 1
• 230000036765 blood level Effects 0.000 description 1
• 210000000476 body water Anatomy 0.000 description 1
• 230000010256 bone deposition Effects 0.000 description 1
• KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
• 239000004327 boric acid Substances 0.000 description 1
• GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 1
• 229960001467 bortezomib Drugs 0.000 description 1
• 238000009395 breeding Methods 0.000 description 1
• 230000001488 breeding effect Effects 0.000 description 1
• MJQUEDHRCUIRLF-TVIXENOKSA-N bryostatin 1 Chemical compound C([C@@H]1CC(/[C@@H]([C@@](C(C)(C)/C=C/2)(O)O1)OC(=O)/C=C/C=C/CCC)=C\C(=O)OC)[C@H]([C@@H](C)O)OC(=O)C[C@H](O)C[C@@H](O1)C[C@H](OC(C)=O)C(C)(C)[C@]1(O)C[C@@H]1C\C(=C\C(=O)OC)C[C@H]\2O1 MJQUEDHRCUIRLF-TVIXENOKSA-N 0.000 description 1
• 229960005539 bryostatin 1 Drugs 0.000 description 1
• 239000007853 buffer solution Substances 0.000 description 1
• DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
• 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
• 229940043253 butylated hydroxyanisole Drugs 0.000 description 1
• CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
• 229910052791 calcium Inorganic materials 0.000 description 1
• 239000011575 calcium Substances 0.000 description 1
• 239000001506 calcium phosphate Substances 0.000 description 1
• 229910000389 calcium phosphate Inorganic materials 0.000 description 1
• 235000011010 calcium phosphates Nutrition 0.000 description 1
• 238000004364 calculation method Methods 0.000 description 1
• 229960000830 captopril Drugs 0.000 description 1
• FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
• 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
• 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
• 239000000969 carrier Substances 0.000 description 1
• 230000022159 cartilage development Effects 0.000 description 1
• 238000012219 cassette mutagenesis Methods 0.000 description 1
• 230000015556 catabolic process Effects 0.000 description 1
• 229960000590 celecoxib Drugs 0.000 description 1
• RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
• 230000010261 cell growth Effects 0.000 description 1
• 239000006285 cell suspension Substances 0.000 description 1
• 210000003169 central nervous system Anatomy 0.000 description 1
• 239000002738 chelating agent Substances 0.000 description 1
• ZXFCRFYULUUSDW-OWXODZSWSA-N chembl2104970 Chemical compound C([C@H]1C2)C3=CC=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2CC(O)=C(C(=O)N)C1=O ZXFCRFYULUUSDW-OWXODZSWSA-N 0.000 description 1
• 239000007795 chemical reaction product Substances 0.000 description 1
• 229960004926 chlorobutanol Drugs 0.000 description 1
• VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
• 229960002023 chloroprocaine Drugs 0.000 description 1
• OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
• 229960001231 choline Drugs 0.000 description 1
• 229960002436 cladribine Drugs 0.000 description 1
• 208000029664 classic familial adenomatous polyposis Diseases 0.000 description 1
• 238000004140 cleaning Methods 0.000 description 1
• 230000007012 clinical effect Effects 0.000 description 1
• 229960002286 clodronic acid Drugs 0.000 description 1
• ACSIXWWBWUQEHA-UHFFFAOYSA-N clodronic acid Chemical compound OP(O)(=O)C(Cl)(Cl)P(O)(O)=O ACSIXWWBWUQEHA-UHFFFAOYSA-N 0.000 description 1
• 238000012761 co-transfection Methods 0.000 description 1
• 239000007931 coated granule Substances 0.000 description 1
• 208000029742 colonic neoplasm Diseases 0.000 description 1
• 239000003086 colorant Substances 0.000 description 1
• 238000004440 column chromatography Methods 0.000 description 1
• 238000002648 combination therapy Methods 0.000 description 1
• 230000006957 competitive inhibition Effects 0.000 description 1
• 230000004154 complement system Effects 0.000 description 1
• 230000006835 compression Effects 0.000 description 1
• 238000007906 compression Methods 0.000 description 1
• 239000012141 concentrate Substances 0.000 description 1
• 235000008504 concentrate Nutrition 0.000 description 1
• 238000012790 confirmation Methods 0.000 description 1
• 239000000356 contaminant Substances 0.000 description 1
• 238000013270 controlled release Methods 0.000 description 1
• OMFXVFTZEKFJBZ-HJTSIMOOSA-N corticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OMFXVFTZEKFJBZ-HJTSIMOOSA-N 0.000 description 1
• 229940111134 coxibs Drugs 0.000 description 1
• 238000011262 co‐therapy Methods 0.000 description 1
• 238000004132 cross linking Methods 0.000 description 1
• 238000002425 crystallisation Methods 0.000 description 1
• 230000008025 crystallization Effects 0.000 description 1
• 239000012228 culture supernatant Substances 0.000 description 1
• 238000012258 culturing Methods 0.000 description 1
• 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
• 229960001305 cysteine hydrochloride Drugs 0.000 description 1
• 230000001086 cytosolic effect Effects 0.000 description 1
• 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
• 231100000599 cytotoxic agent Toxicity 0.000 description 1
• 239000002619 cytotoxin Substances 0.000 description 1
• 230000002354 daily effect Effects 0.000 description 1
• 229960000975 daunorubicin Drugs 0.000 description 1
• STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
• ZESRJSPZRDMNHY-UHFFFAOYSA-N de-oxy corticosterone Natural products O=C1CCC2(C)C3CCC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 ZESRJSPZRDMNHY-UHFFFAOYSA-N 0.000 description 1
• 239000003954 decarboxylase inhibitor Substances 0.000 description 1
• 229960003603 decitabine Drugs 0.000 description 1
• 230000002950 deficient Effects 0.000 description 1
• 235000010389 delta-tocopherol Nutrition 0.000 description 1
• BTNBMQIHCRIGOU-UHFFFAOYSA-N delta-tocotrienol Natural products CC(=CCCC(=CCCC(=CCCOC1(C)CCc2cc(O)cc(C)c2O1)C)C)C BTNBMQIHCRIGOU-UHFFFAOYSA-N 0.000 description 1
• 229940119740 deoxycorticosterone Drugs 0.000 description 1
• DLVJMFOLJOOWFS-INMLLLKOSA-N depudecin Chemical compound C[C@@H](O)[C@@H]1O[C@H]1\C=C\[C@H]1[C@H]([C@H](O)C=C)O1 DLVJMFOLJOOWFS-INMLLLKOSA-N 0.000 description 1
• 230000000368 destabilizing effect Effects 0.000 description 1
• 239000008121 dextrose Substances 0.000 description 1
• 238000003745 diagnosis Methods 0.000 description 1
• 150000001991 dicarboxylic acids Chemical class 0.000 description 1
• ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
• 229940043237 diethanolamine Drugs 0.000 description 1
• 102000004419 dihydrofolate reductase Human genes 0.000 description 1
• OTKJDMGTUTTYMP-UHFFFAOYSA-N dihydrosphingosine Natural products CCCCCCCCCCCCCCCC(O)C(N)CO OTKJDMGTUTTYMP-UHFFFAOYSA-N 0.000 description 1
• UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
• 238000006471 dimerization reaction Methods 0.000 description 1
• 230000007646 directional migration Effects 0.000 description 1
• 238000011038 discontinuous diafiltration by volume reduction Methods 0.000 description 1
• 208000037765 diseases and disorders Diseases 0.000 description 1
• 239000007884 disintegrant Substances 0.000 description 1
• 239000002270 dispersing agent Substances 0.000 description 1
• 210000001198 duodenum Anatomy 0.000 description 1
• FSIRXIHZBIXHKT-MHTVFEQDSA-N edatrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CC(CC)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FSIRXIHZBIXHKT-MHTVFEQDSA-N 0.000 description 1
• 229950006700 edatrexate Drugs 0.000 description 1
• 230000013020 embryo development Effects 0.000 description 1
• 229960000873 enalapril Drugs 0.000 description 1
• GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 1
• INVTYAOGFAGBOE-UHFFFAOYSA-N entinostat Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC(=O)OCC1=CC=CN=C1 INVTYAOGFAGBOE-UHFFFAOYSA-N 0.000 description 1
• 230000007613 environmental effect Effects 0.000 description 1
• 230000002255 enzymatic effect Effects 0.000 description 1
• 229940116977 epidermal growth factor Drugs 0.000 description 1
• 210000003999 epithelial cell of bile duct Anatomy 0.000 description 1
• HESCAJZNRMSMJG-KKQRBIROSA-N epothilone A Chemical compound C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HESCAJZNRMSMJG-KKQRBIROSA-N 0.000 description 1
• 150000003883 epothilone derivatives Chemical class 0.000 description 1
• 229960005309 estradiol Drugs 0.000 description 1
• 229930182833 estradiol Natural products 0.000 description 1
• 102000015694 estrogen receptors Human genes 0.000 description 1
• 108010038795 estrogen receptors Proteins 0.000 description 1
• 235000019441 ethanol Nutrition 0.000 description 1
• BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
• 235000019325 ethyl cellulose Nutrition 0.000 description 1
• 229920001249 ethyl cellulose Polymers 0.000 description 1
• LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
• 229940093471 ethyl oleate Drugs 0.000 description 1
• 239000005038 ethylene vinyl acetate Substances 0.000 description 1
• 229940012017 ethylenediamine Drugs 0.000 description 1
• 229960004945 etoricoxib Drugs 0.000 description 1
• MNJVRJDLRVPLFE-UHFFFAOYSA-N etoricoxib Chemical compound C1=NC(C)=CC=C1C1=NC=C(Cl)C=C1C1=CC=C(S(C)(=O)=O)C=C1 MNJVRJDLRVPLFE-UHFFFAOYSA-N 0.000 description 1
• 230000003203 everyday effect Effects 0.000 description 1
• 239000004744 fabric Substances 0.000 description 1
• 229950011548 fadrozole Drugs 0.000 description 1
• 229940012952 fibrinogen Drugs 0.000 description 1
• LIYGYAHYXQDGEP-UHFFFAOYSA-N firefly oxyluciferin Natural products Oc1csc(n1)-c1nc2ccc(O)cc2s1 LIYGYAHYXQDGEP-UHFFFAOYSA-N 0.000 description 1
• 239000000796 flavoring agent Substances 0.000 description 1
• 238000000684 flow cytometry Methods 0.000 description 1
• 229960000390 fludarabine Drugs 0.000 description 1
• 229960005304 fludarabine phosphate Drugs 0.000 description 1
• 229940014144 folate Drugs 0.000 description 1
• OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 1
• 235000019152 folic acid Nutrition 0.000 description 1
• 239000011724 folic acid Substances 0.000 description 1
• 239000004052 folic acid antagonist Substances 0.000 description 1
• 230000003325 follicular Effects 0.000 description 1
• 235000013355 food flavoring agent Nutrition 0.000 description 1
• 229960004421 formestane Drugs 0.000 description 1
• OSVMTWJCGUFAOD-KZQROQTASA-N formestane Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1O OSVMTWJCGUFAOD-KZQROQTASA-N 0.000 description 1
• 229960002490 fosinopril Drugs 0.000 description 1
• 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
• 125000002446 fucosyl group Chemical group C1([C@@H](O)[C@H](O)[C@H](O)[C@@H](O1)C)* 0.000 description 1
• 238000002825 functional assay Methods 0.000 description 1
• 102000013069 gamma-Crystallins Human genes 0.000 description 1
• 108010079934 gamma-Crystallins Proteins 0.000 description 1
• OTXNTMVVOOBZCV-YMCDKREISA-N gamma-Tocotrienol Natural products Oc1c(C)c(C)c2O[C@@](CC/C=C(\CC/C=C(\CC/C=C(\C)/C)/C)/C)(C)CCc2c1 OTXNTMVVOOBZCV-YMCDKREISA-N 0.000 description 1
• 235000010382 gamma-tocopherol Nutrition 0.000 description 1
• WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
• 239000007789 gas Substances 0.000 description 1
• 230000002496 gastric effect Effects 0.000 description 1
• 210000001035 gastrointestinal tract Anatomy 0.000 description 1
• 238000001502 gel electrophoresis Methods 0.000 description 1
• 238000012637 gene transfection Methods 0.000 description 1
• 238000012252 genetic analysis Methods 0.000 description 1
• 230000002068 genetic effect Effects 0.000 description 1
• 238000010362 genome editing Methods 0.000 description 1
• 210000004907 gland Anatomy 0.000 description 1
• 239000003292 glue Substances 0.000 description 1
• 235000013922 glutamic acid Nutrition 0.000 description 1
• 239000004220 glutamic acid Substances 0.000 description 1
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
• 150000002334 glycols Chemical class 0.000 description 1
• 102000045442 glycosyltransferase activity proteins Human genes 0.000 description 1
• 108700014210 glycosyltransferase activity proteins Proteins 0.000 description 1
• 239000002474 gonadorelin antagonist Substances 0.000 description 1
• 239000003979 granulating agent Substances 0.000 description 1
• 238000005469 granulation Methods 0.000 description 1
• 230000003179 granulation Effects 0.000 description 1
• 210000003714 granulocyte Anatomy 0.000 description 1
• 239000005090 green fluorescent protein Substances 0.000 description 1
• 229940093915 gynecological organic acid Drugs 0.000 description 1
• 210000002216 heart Anatomy 0.000 description 1
• 210000002443 helper t lymphocyte Anatomy 0.000 description 1
• 108060003552 hemocyanin Proteins 0.000 description 1
• 230000002440 hepatic effect Effects 0.000 description 1
• 238000004128 high performance liquid chromatography Methods 0.000 description 1
• 229940121372 histone deacetylase inhibitor Drugs 0.000 description 1
• 239000003276 histone deacetylase inhibitor Substances 0.000 description 1
• 235000012907 honey Nutrition 0.000 description 1
• 229940125697 hormonal agent Drugs 0.000 description 1
• 229940088597 hormone Drugs 0.000 description 1
• 239000005556 hormone Substances 0.000 description 1
• 108091008039 hormone receptors Proteins 0.000 description 1
• 102000053365 human CHUK Human genes 0.000 description 1
• 102000047119 human OCA2 Human genes 0.000 description 1
• 102000051411 human PSMA6 Human genes 0.000 description 1
• 102000056245 human TLE5 Human genes 0.000 description 1
• 210000004754 hybrid cell Anatomy 0.000 description 1
• 229960000890 hydrocortisone Drugs 0.000 description 1
• XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
• 229910000043 hydrogen iodide Inorganic materials 0.000 description 1
• 229960001330 hydroxycarbamide Drugs 0.000 description 1
• 230000036031 hyperthermia Effects 0.000 description 1
• 238000009217 hyperthermia therapy Methods 0.000 description 1
• 229960005236 ibandronic acid Drugs 0.000 description 1
• 229960003685 imatinib mesylate Drugs 0.000 description 1
• YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 description 1
• 230000000984 immunochemical effect Effects 0.000 description 1
• 230000002163 immunogen Effects 0.000 description 1
• 230000016784 immunoglobulin production Effects 0.000 description 1
• 238000002991 immunohistochemical analysis Methods 0.000 description 1
• 239000000367 immunologic factor Substances 0.000 description 1
• 229960003444 immunosuppressant agent Drugs 0.000 description 1
• 239000003018 immunosuppressive agent Substances 0.000 description 1
• 230000001771 impaired effect Effects 0.000 description 1
• 230000000415 inactivating effect Effects 0.000 description 1
• 238000010348 incorporation Methods 0.000 description 1
• 230000001939 inductive effect Effects 0.000 description 1
• 230000004054 inflammatory process Effects 0.000 description 1
• 230000028709 inflammatory response Effects 0.000 description 1
• 229940079322 interferon Drugs 0.000 description 1
• 229960003130 interferon gamma Drugs 0.000 description 1
• 238000001361 intraarterial administration Methods 0.000 description 1
• 239000007928 intraperitoneal injection Substances 0.000 description 1
• 238000007913 intrathecal administration Methods 0.000 description 1
• 238000010253 intravenous injection Methods 0.000 description 1
• 229940084651 iressa Drugs 0.000 description 1
• 230000001788 irregular Effects 0.000 description 1
• 238000002955 isolation Methods 0.000 description 1
• HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 description 1
• 150000002537 isoquinolines Chemical class 0.000 description 1
• 230000009916 joint effect Effects 0.000 description 1
• 229930027917 kanamycin Natural products 0.000 description 1
• SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
• 229960000318 kanamycin Drugs 0.000 description 1
• 229930182823 kanamycin A Natural products 0.000 description 1
• 229960004125 ketoconazole Drugs 0.000 description 1
• 210000003292 kidney cell Anatomy 0.000 description 1
• 230000003902 lesion Effects 0.000 description 1
• 231100001231 less toxic Toxicity 0.000 description 1
• 230000004576 lipid-binding Effects 0.000 description 1
• 239000007788 liquid Substances 0.000 description 1
• 229960002394 lisinopril Drugs 0.000 description 1
• RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 description 1
• YROQEQPFUCPDCP-UHFFFAOYSA-N losoxantrone Chemical compound OCCNCCN1N=C2C3=CC=CC(O)=C3C(=O)C3=C2C1=CC=C3NCCNCCO YROQEQPFUCPDCP-UHFFFAOYSA-N 0.000 description 1
• 229950008745 losoxantrone Drugs 0.000 description 1
• 239000000314 lubricant Substances 0.000 description 1
• 229960000994 lumiracoxib Drugs 0.000 description 1
• 201000005202 lung cancer Diseases 0.000 description 1
• 208000020816 lung neoplasm Diseases 0.000 description 1
• 210000001165 lymph node Anatomy 0.000 description 1
• 230000000527 lymphocytic effect Effects 0.000 description 1
• 229920002521 macromolecule Polymers 0.000 description 1
• 229910052749 magnesium Inorganic materials 0.000 description 1
• 210000005075 mammary gland Anatomy 0.000 description 1
• 150000008146 mannosides Chemical class 0.000 description 1
• OCSMOTCMPXTDND-OUAUKWLOSA-N marimastat Chemical class CNC(=O)[C@H](C(C)(C)C)NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO OCSMOTCMPXTDND-OUAUKWLOSA-N 0.000 description 1
• 238000002483 medication Methods 0.000 description 1
• 229940126601 medicinal product Drugs 0.000 description 1
• SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
• 229960001924 melphalan Drugs 0.000 description 1
• 108020004999 messenger RNA Proteins 0.000 description 1
• 230000004060 metabolic process Effects 0.000 description 1
• 229910052751 metal Inorganic materials 0.000 description 1
• 239000002184 metal Substances 0.000 description 1
• 208000037819 metastatic cancer Diseases 0.000 description 1
• 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
• 229930182817 methionine Natural products 0.000 description 1
• 239000004530 micro-emulsion Substances 0.000 description 1
• 238000001471 micro-filtration Methods 0.000 description 1
• 244000005700 microbiome Species 0.000 description 1
• 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
• 230000003278 mimic effect Effects 0.000 description 1
• 150000007522 mineralic acids Chemical class 0.000 description 1
• 239000007758 minimum essential medium Substances 0.000 description 1
• 229960005170 moexipril Drugs 0.000 description 1
• 210000003003 monocyte-macrophage precursor cell Anatomy 0.000 description 1
• VYGYNVZNSSTDLJ-HKCOAVLJSA-N monorden Natural products CC1CC2OC2C=C/C=C/C(=O)CC3C(C(=CC(=C3Cl)O)O)C(=O)O1 VYGYNVZNSSTDLJ-HKCOAVLJSA-N 0.000 description 1
• 230000000877 morphologic effect Effects 0.000 description 1
• 108700005673 mouse S1 Proteins 0.000 description 1
• 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
• 210000004400 mucous membrane Anatomy 0.000 description 1
• 210000000663 muscle cell Anatomy 0.000 description 1
• 210000004457 myocytus nodalis Anatomy 0.000 description 1
• XJGOPYWCSIEHLX-UHFFFAOYSA-N n-(4-tert-butylphenyl)-4-(pyridin-4-ylmethyl)isoquinolin-1-amine Chemical compound C1=CC(C(C)(C)C)=CC=C1NC(C1=CC=CC=C11)=NC=C1CC1=CC=NC=C1 XJGOPYWCSIEHLX-UHFFFAOYSA-N 0.000 description 1
• 239000002105 nanoparticle Substances 0.000 description 1
• 239000013642 negative control Substances 0.000 description 1
• 230000010807 negative regulation of binding Effects 0.000 description 1
• CTMCWCONSULRHO-UHQPFXKFSA-N nemorubicin Chemical compound C1CO[C@H](OC)CN1[C@@H]1[C@H](O)[C@H](C)O[C@@H](O[C@@H]2C3=C(O)C=4C(=O)C5=C(OC)C=CC=C5C(=O)C=4C(O)=C3C[C@](O)(C2)C(=O)CO)C1 CTMCWCONSULRHO-UHQPFXKFSA-N 0.000 description 1
• 229950010159 nemorubicin Drugs 0.000 description 1
• 201000008026 nephroblastoma Diseases 0.000 description 1
• 210000000944 nerve tissue Anatomy 0.000 description 1
• OSTGTTZJOCZWJG-UHFFFAOYSA-N nitrosourea Chemical compound NC(=O)N=NO OSTGTTZJOCZWJG-UHFFFAOYSA-N 0.000 description 1
• 239000002687 nonaqueous vehicle Substances 0.000 description 1
• 230000030648 nucleus localization Effects 0.000 description 1
• 235000008390 olive oil Nutrition 0.000 description 1
• 239000004006 olive oil Substances 0.000 description 1
• 210000000056 organ Anatomy 0.000 description 1
• 150000007524 organic acids Chemical class 0.000 description 1
• 235000005985 organic acids Nutrition 0.000 description 1
• 150000002895 organic esters Chemical class 0.000 description 1
• 230000004072 osteoblast differentiation Effects 0.000 description 1
• 230000002188 osteogenic effect Effects 0.000 description 1
• 210000001672 ovary Anatomy 0.000 description 1
• JJVOROULKOMTKG-UHFFFAOYSA-N oxidized Photinus luciferin Chemical compound S1C2=CC(O)=CC=C2N=C1C1=NC(=O)CS1 JJVOROULKOMTKG-UHFFFAOYSA-N 0.000 description 1
• 238000004806 packaging method and process Methods 0.000 description 1
• WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 description 1
• 229960003978 pamidronic acid Drugs 0.000 description 1
• FPOHNWQLNRZRFC-ZHACJKMWSA-N panobinostat Chemical compound CC=1NC2=CC=CC=C2C=1CCNCC1=CC=C(\C=C\C(=O)NO)C=C1 FPOHNWQLNRZRFC-ZHACJKMWSA-N 0.000 description 1
• 229960005184 panobinostat Drugs 0.000 description 1
• 230000008506 pathogenesis Effects 0.000 description 1
• 230000001575 pathological effect Effects 0.000 description 1
• 230000001991 pathophysiological effect Effects 0.000 description 1
• WBXPDJSOTKVWSJ-ZDUSSCGKSA-N pemetrexed Chemical compound C=1NC=2NC(N)=NC(=O)C=2C=1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 WBXPDJSOTKVWSJ-ZDUSSCGKSA-N 0.000 description 1
• 229960005079 pemetrexed Drugs 0.000 description 1
• 230000035515 penetration Effects 0.000 description 1
• 229940049954 penicillin Drugs 0.000 description 1
• 229960002340 pentostatin Drugs 0.000 description 1
• FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 1
• 238000012510 peptide mapping method Methods 0.000 description 1
• 229960002582 perindopril Drugs 0.000 description 1
• IPVQLZZIHOAWMC-QXKUPLGCSA-N perindopril Chemical compound C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H]21 IPVQLZZIHOAWMC-QXKUPLGCSA-N 0.000 description 1
• 210000005259 peripheral blood Anatomy 0.000 description 1
• 239000011886 peripheral blood Substances 0.000 description 1
• 108700010839 phage proteins Proteins 0.000 description 1
• 210000001539 phagocyte Anatomy 0.000 description 1
• 229940127557 pharmaceutical product Drugs 0.000 description 1
• 229960003742 phenol Drugs 0.000 description 1
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
• 229910052698 phosphorus Inorganic materials 0.000 description 1
• 230000026731 phosphorylation Effects 0.000 description 1
• 238000006366 phosphorylation reaction Methods 0.000 description 1
• 239000003504 photosensitizing agent Substances 0.000 description 1
• 230000004962 physiological condition Effects 0.000 description 1
• 101150037186 pkc-1 gene Proteins 0.000 description 1
• 239000013600 plasmid vector Substances 0.000 description 1
• 229920003023 plastic Polymers 0.000 description 1
• 239000004033 plastic Substances 0.000 description 1
• 150000003057 platinum Chemical class 0.000 description 1
• 229910052697 platinum Inorganic materials 0.000 description 1
• 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
• 229920000747 poly(lactic acid) Polymers 0.000 description 1
• 230000008488 polyadenylation Effects 0.000 description 1
• 239000004633 polyglycolic acid Substances 0.000 description 1
• 239000004626 polylactic acid Substances 0.000 description 1
• 238000006116 polymerization reaction Methods 0.000 description 1
• 229920001155 polypropylene Polymers 0.000 description 1
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
• 230000008092 positive effect Effects 0.000 description 1
• 208000001685 postmenopausal osteoporosis Diseases 0.000 description 1
• 230000001323 posttranslational effect Effects 0.000 description 1
• 239000011591 potassium Substances 0.000 description 1
• 229910052700 potassium Inorganic materials 0.000 description 1
• QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
• 238000001556 precipitation Methods 0.000 description 1
• 238000004321 preservation Methods 0.000 description 1
• 229950003608 prinomastat Drugs 0.000 description 1
• YKPYIPVDTNNYCN-INIZCTEOSA-N prinomastat Chemical compound ONC(=O)[C@H]1C(C)(C)SCCN1S(=O)(=O)C(C=C1)=CC=C1OC1=CC=NC=C1 YKPYIPVDTNNYCN-INIZCTEOSA-N 0.000 description 1
• MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
• 229960004919 procaine Drugs 0.000 description 1
• 230000000644 propagated effect Effects 0.000 description 1
• 239000000473 propyl gallate Substances 0.000 description 1
• 235000010388 propyl gallate Nutrition 0.000 description 1
• 229940075579 propyl gallate Drugs 0.000 description 1
• 230000026938 proteasomal ubiquitin-dependent protein catabolic process Effects 0.000 description 1
• 108010071967 protein K Proteins 0.000 description 1
• 229960000856 protein c Drugs 0.000 description 1
• 230000020978 protein processing Effects 0.000 description 1
• 238000001742 protein purification Methods 0.000 description 1
• 230000012743 protein tagging Effects 0.000 description 1
• 230000004850 protein–protein interaction Effects 0.000 description 1
• 230000006337 proteolytic cleavage Effects 0.000 description 1
• 239000002212 purine nucleoside Substances 0.000 description 1
• 150000003212 purines Chemical class 0.000 description 1
• 238000003908 quality control method Methods 0.000 description 1
• 238000004445 quantitative analysis Methods 0.000 description 1
• 125000002943 quinolinyl group Chemical class N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
• AECPBJMOGBFQDN-YMYQVXQQSA-N radicicol Chemical compound C1CCCC(=O)C[C@H]2[C@H](Cl)C(=O)CC(=O)[C@H]2C(=O)O[C@H](C)C[C@H]2O[C@@H]21 AECPBJMOGBFQDN-YMYQVXQQSA-N 0.000 description 1
• 229930192524 radicicol Natural products 0.000 description 1
• 229960004622 raloxifene Drugs 0.000 description 1
• GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 1
• 229960003401 ramipril Drugs 0.000 description 1
• HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 description 1
• 238000002708 random mutagenesis Methods 0.000 description 1
• 230000006798 recombination Effects 0.000 description 1
• 238000005215 recombination Methods 0.000 description 1
• 238000000611 regression analysis Methods 0.000 description 1
• 230000008844 regulatory mechanism Effects 0.000 description 1
• 230000008439 repair process Effects 0.000 description 1
• 230000000717 retained effect Effects 0.000 description 1
• 229930002330 retinoic acid Natural products 0.000 description 1
• 238000012770 revaccination Methods 0.000 description 1
• 206010039073 rheumatoid arthritis Diseases 0.000 description 1
• 210000003705 ribosome Anatomy 0.000 description 1
• 239000011435 rock Substances 0.000 description 1
• 229960000371 rofecoxib Drugs 0.000 description 1
• RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 1
• 229950005230 rogletimide Drugs 0.000 description 1
• QXKJWHWUDVQATH-UHFFFAOYSA-N rogletimide Chemical compound C=1C=NC=CC=1C1(CC)CCC(=O)NC1=O QXKJWHWUDVQATH-UHFFFAOYSA-N 0.000 description 1
• OHRURASPPZQGQM-GCCNXGTGSA-N romidepsin Chemical compound O1C(=O)[C@H](C(C)C)NC(=O)C(=C/C)/NC(=O)[C@H]2CSSCC\C=C\[C@@H]1CC(=O)N[C@H](C(C)C)C(=O)N2 OHRURASPPZQGQM-GCCNXGTGSA-N 0.000 description 1
• VHXNKPBCCMUMSW-FQEVSTJZSA-N rubitecan Chemical compound C1=CC([N+]([O-])=O)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VHXNKPBCCMUMSW-FQEVSTJZSA-N 0.000 description 1
• 229950009213 rubitecan Drugs 0.000 description 1
• 229950008902 safingol Drugs 0.000 description 1
• 239000004576 sand Substances 0.000 description 1
• 108010008595 sarcoma-associated antigen S1 Proteins 0.000 description 1
• 190014017285 satraplatin Chemical compound 0.000 description 1
• 229960005399 satraplatin Drugs 0.000 description 1
• 238000007790 scraping Methods 0.000 description 1
• 230000008313 sensitization Effects 0.000 description 1
• 238000000926 separation method Methods 0.000 description 1
• 238000013207 serial dilution Methods 0.000 description 1
• 239000004017 serum-free culture medium Substances 0.000 description 1
• 208000002491 severe combined immunodeficiency Diseases 0.000 description 1
• 230000011664 signaling Effects 0.000 description 1
• 210000002027 skeletal muscle Anatomy 0.000 description 1
• WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
• 229910000342 sodium bisulfate Inorganic materials 0.000 description 1
• 229940100996 sodium bisulfate Drugs 0.000 description 1
• 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
• 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
• HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
• 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
• 229940001584 sodium metabisulfite Drugs 0.000 description 1
• 235000010262 sodium metabisulphite Nutrition 0.000 description 1
• 239000012453 solvate Substances 0.000 description 1
• 210000001082 somatic cell Anatomy 0.000 description 1
• 230000000392 somatic effect Effects 0.000 description 1
• 235000010199 sorbic acid Nutrition 0.000 description 1
• 239000004334 sorbic acid Substances 0.000 description 1
• 229940075582 sorbic acid Drugs 0.000 description 1
• 235000014347 soups Nutrition 0.000 description 1
• OTKJDMGTUTTYMP-ZWKOTPCHSA-N sphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@@H](N)CO OTKJDMGTUTTYMP-ZWKOTPCHSA-N 0.000 description 1
• 239000003381 stabilizer Substances 0.000 description 1
• 230000000087 stabilizing effect Effects 0.000 description 1
• 230000010473 stable expression Effects 0.000 description 1
• 238000010186 staining Methods 0.000 description 1
• 235000019698 starch Nutrition 0.000 description 1
• 238000007619 statistical method Methods 0.000 description 1
• 230000003637 steroidlike Effects 0.000 description 1
• 230000000638 stimulation Effects 0.000 description 1
• 239000011550 stock solution Substances 0.000 description 1
• 210000002784 stomach Anatomy 0.000 description 1
• 238000013517 stratification Methods 0.000 description 1
• 229960005322 streptomycin Drugs 0.000 description 1
• 101150018444 sub2 gene Proteins 0.000 description 1
• KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
• 239000007940 sugar coated tablet Substances 0.000 description 1
• 239000000829 suppository Substances 0.000 description 1
• 238000001356 surgical procedure Methods 0.000 description 1
• 239000012730 sustained-release form Substances 0.000 description 1
• 208000011580 syndromic disease Diseases 0.000 description 1
• 239000006188 syrup Substances 0.000 description 1
• 235000020357 syrup Nutrition 0.000 description 1
• 239000011975 tartaric acid Substances 0.000 description 1
• 235000002906 tartaric acid Nutrition 0.000 description 1
• 229960004964 temozolomide Drugs 0.000 description 1
• ISIJQEHRDSCQIU-UHFFFAOYSA-N tert-butyl 2,7-diazaspiro[4.5]decane-7-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCCC11CNCC1 ISIJQEHRDSCQIU-UHFFFAOYSA-N 0.000 description 1
• 229960005353 testolactone Drugs 0.000 description 1
• BPEWUONYVDABNZ-DZBHQSCQSA-N testolactone Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(OC(=O)CC4)[C@@H]4[C@@H]3CCC2=C1 BPEWUONYVDABNZ-DZBHQSCQSA-N 0.000 description 1
• 229930101283 tetracycline Natural products 0.000 description 1
• 229960002180 tetracycline Drugs 0.000 description 1
• 235000019364 tetracycline Nutrition 0.000 description 1
• 150000003522 tetracyclines Chemical class 0.000 description 1
• 229960003433 thalidomide Drugs 0.000 description 1
• 210000001541 thymus gland Anatomy 0.000 description 1
• 229960005324 tiludronic acid Drugs 0.000 description 1
• 230000036962 time dependent Effects 0.000 description 1
• 229960003087 tioguanine Drugs 0.000 description 1
• AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 1
• 229960000984 tocofersolan Drugs 0.000 description 1
• 238000003325 tomography Methods 0.000 description 1
• 238000011200 topical administration Methods 0.000 description 1
• 230000000699 topical effect Effects 0.000 description 1
• 231100000331 toxic Toxicity 0.000 description 1
• 230000002588 toxic effect Effects 0.000 description 1
• 230000001988 toxicity Effects 0.000 description 1
• 231100000419 toxicity Toxicity 0.000 description 1
• 230000002110 toxicologic effect Effects 0.000 description 1
• 231100000759 toxicological effect Toxicity 0.000 description 1
• 229960002051 trandolapril Drugs 0.000 description 1
• 239000012096 transfection reagent Substances 0.000 description 1
• 238000012546 transfer Methods 0.000 description 1
• 238000012451 transgenic animal system Methods 0.000 description 1
• 230000001052 transient effect Effects 0.000 description 1
• 230000005945 translocation Effects 0.000 description 1
• 102000035160 transmembrane proteins Human genes 0.000 description 1
• 108091005703 transmembrane proteins Proteins 0.000 description 1
• 108010060597 trapoxin A Proteins 0.000 description 1
• 238000011269 treatment regimen Methods 0.000 description 1
• 229960001727 tretinoin Drugs 0.000 description 1
• 229960005294 triamcinolone Drugs 0.000 description 1
• GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
• RTKIYFITIVXBLE-QEQCGCAPSA-N trichostatin A Chemical compound ONC(=O)/C=C/C(/C)=C/[C@@H](C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-QEQCGCAPSA-N 0.000 description 1
• ZMANZCXQSJIPKH-UHFFFAOYSA-N triethylamine Natural products CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 1
• 229960001670 trilostane Drugs 0.000 description 1
• KVJXBPDAXMEYOA-CXANFOAXSA-N trilostane Chemical compound OC1=C(C#N)C[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@@]32O[C@@H]31 KVJXBPDAXMEYOA-CXANFOAXSA-N 0.000 description 1
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
• 230000005740 tumor formation Effects 0.000 description 1
• 230000005760 tumorsuppression Effects 0.000 description 1
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
• 230000034512 ubiquitination Effects 0.000 description 1
• 238000010798 ubiquitination Methods 0.000 description 1
• 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
• 241001515965 unidentified phage Species 0.000 description 1
• 210000002700 urine Anatomy 0.000 description 1
• VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
• 238000001291 vacuum drying Methods 0.000 description 1
• 229910052720 vanadium Inorganic materials 0.000 description 1
• YCOYDOIWSSHVCK-UHFFFAOYSA-N vatalanib Chemical compound C1=CC(Cl)=CC=C1NC(C1=CC=CC=C11)=NN=C1CC1=CC=NC=C1 YCOYDOIWSSHVCK-UHFFFAOYSA-N 0.000 description 1
• 235000015112 vegetable and seed oil Nutrition 0.000 description 1
• 239000008158 vegetable oil Substances 0.000 description 1
• 235000013311 vegetables Nutrition 0.000 description 1
• 239000003981 vehicle Substances 0.000 description 1
• 229960003048 vinblastine Drugs 0.000 description 1
• JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
• 229960004528 vincristine Drugs 0.000 description 1
• OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
• OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
• GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
• 229960002066 vinorelbine Drugs 0.000 description 1
• 238000012800 visualization Methods 0.000 description 1
• XLMPPFTZALNBFS-INIZCTEOSA-N vorozole Chemical compound C1([C@@H](C2=CC=C3N=NN(C3=C2)C)N2N=CN=C2)=CC=C(Cl)C=C1 XLMPPFTZALNBFS-INIZCTEOSA-N 0.000 description 1
• 229920003169 water-soluble polymer Polymers 0.000 description 1
• 230000003442 weekly effect Effects 0.000 description 1
• 238000005303 weighing Methods 0.000 description 1
• RZFHLOLGZPDCHJ-XZXLULOTSA-N α-Tocotrienol Chemical compound OC1=C(C)C(C)=C2O[C@@](CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1C RZFHLOLGZPDCHJ-XZXLULOTSA-N 0.000 description 1
• 239000011730 α-tocotrienol Substances 0.000 description 1
• 235000019145 α-tocotrienol Nutrition 0.000 description 1
• 239000002478 γ-tocopherol Substances 0.000 description 1
• QUEDXNHFTDJVIY-DQCZWYHMSA-N γ-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-DQCZWYHMSA-N 0.000 description 1
• 239000011722 γ-tocotrienol Substances 0.000 description 1
• 235000019150 γ-tocotrienol Nutrition 0.000 description 1
• OTXNTMVVOOBZCV-WAZJVIJMSA-N γ-tocotrienol Chemical compound OC1=C(C)C(C)=C2O[C@@](CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1 OTXNTMVVOOBZCV-WAZJVIJMSA-N 0.000 description 1
• 239000002446 δ-tocopherol Substances 0.000 description 1
• 239000011729 δ-tocotrienol Substances 0.000 description 1
• 235000019144 δ-tocotrienol Nutrition 0.000 description 1
• ODADKLYLWWCHNB-LDYBVBFYSA-N δ-tocotrienol Chemical compound OC1=CC(C)=C2O[C@@](CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1 ODADKLYLWWCHNB-LDYBVBFYSA-N 0.000 description 1